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Abstract
In clinical evaluation processes, meta-analysis is a statistical methodology to synthesise
results of several trials for the purpose of quantitatively summarising the evidence expressed
as a treatment effect (e.g, mean treatment difference for continuous outcomes). Especially in
clinical perspectives, there is a growing interest in extending meta-analysis beyond estimat-
ing an overall treatment effect, and. to produce results tailored to the individual patient or
clinically relevant subgroups. Meta-regression (MR) is a technique for modeling relationships
between the treatment effect and trial-level covariates, and also can be used for assessing how
the patient characteristics affect the clinical efiectiveness in the context of meta-analysis.
However, most meta-analysis methods build models on,aggregate data (AD) obtained by
summarising individual patient data (IPD) which should have beerr measured originally in
each trial, and thus a pooled treatment effect is estimated with ignoring scheme of sampling
IPD. For this reason, the MR model have often been criticised. The MR model incorporates
covariates as summary statistics on background factors of patients, such as a mean age and
a proportion of male patients in each trial. This means that the patient characteristics are
evaluated expediently with trial-level covariates in place of patient-level covariates. It causes
a technical issue that is referred to as ecological bias, and leads to a Iimitation in interpre-
tation. In pa,rticular, it is well known that, for a treatment-covariate interaction between
a clinical treatment and a patient bharacteristic, a test using the MR model has seriously
lower statistical power than that using the IPD-based model. Note that, for the inference
of the treatment-covariate interaction, the MR model yields a result of just an 'across-trial
interaction efiect' between the treatment efiect estimates and mean covariate values, not a
'within-trial interaction efiect' between individual outcomes and individual covariate values.
As alternative solutions to this problems, some meta-analysis methods using IPD have
been suggested. In these methods, once the original IPD including patient-level covariates
are collected from all trials involved, any flexible statistical approaches, such as multilevel
models and hierarchical random effect models, are applied to the IPD. Meta-analyses based
on IPD allow one to achieve much more meaningful evaluation on the treatment-covariate
interaction by separating it into the across-trial and the within-trial efiect; in particular, the
IPD meta-analysis is an only way to assess the within-trial interaction efiect. However, use of
the IPD may have a disadvantage related to their resources, such as substantial time and costs
to obtain and pr6cess the IPDo And also,practitioners cannot alwars collect the IPD ttom
all trials because the IPD Inight have beOn lost Or destroyed.For this reason,it has becolne
ivreasingly important to consider situations where some trials pЮ宙de IPD(IPD t ials)and
the others provide only AD(AD triab)。Somё researchers have abёdy illvestigated how to
combine IPD and AD in meta―analySis,especially when tおat品nt_cOvariate interaction is of
interest.
■om these backgrounds,we prOpose a meta―analysis m thod for estimating b6th the
across‐trial and the within‐trial i teraction.For the caSe that all trialS prOvide only AD,
we■rst assume an IPD metttanalysis model including parameters of the across―t五4 and
the within―rial interaction elbct,and then llllarginalise the density of IPD with respect to
imiSSing IPD.This proce,s produces a like五hood f r the AD available,and allowS one to get
information on the within―trialin eraction by meta―analysing several AD t五als.we en3phasise
that the wtthin―trial intёraction can be approximately estittated by using this likehhood even
ifonly the Ap are available ttom eadh trialo Actu嵐崎,SO e simulatiott studies suggested that
the proposed IIlethod has potential benellts to the inference of the within‐trial interaction in
comparison with the existing MR approacho When S6me trials pЮvide IPD and the others
provide only AD,the proposed method is sil■■ply extendOd to combillle IPD and ADo There,the
likelihood for parameters to be estimtted is given by product of a hkehhood for the IPD trials
and the marginを山sed likelihood for the AD trials.This again allows one to get information
on the within―tiialinteraction ibm the AD trials.ThЮug  simulation studieS,the pЮposed
nlethod provided sma■er biases and smaller lnean―square errors ibr estillnator of the within‐
trial interaction in comparison with some e対Sting lllleta―a alysis IIIlethods,especially wh〕n
the proportiOn of available IPD was sman.And 4sO,Simulation studies investigated hOw the
proportion of available IPE)arects the biases and the mean…squt e errors for estilnator of
the within―riaHnteraction obtailled ttom the pFopOSed methol・These resuns could。●ra
llseful guidance ifone considers how many IPD t五a卜shOuld be conected to presewe a deshed
level of statistical power.Note that the prOposed method is applicable when parameters tO
be estiIIlated can be asslllned as fⅨed elbcts;so that the treatllllent efFect and the treatment‐
covariate inteFattion efFects are assllmed to be common across trials.
As a breakthrough of the e対sting meta―analysis methёds,we pЮpose a meta―alalysis
method based on simulated IPD(SIPD),whiCh recOistructS the missing IPD for each trial
and the,applies a standard IPD meta―analySiS ttOd lto each SIPDo We here discuss two types
of samphng procedllres for generating the SIPD:frequentist and Bayesian prOcedllres.Since
the proposed method based on SIPD also uses the scheme of marginalising the missing IPD,
any advantages mentioned above are held in this framework. When some trials provide IPD
and the others provide only AD, the proposed method reconstructs the missing IPD from
the AD trials and then meta-analyses each set of SIPD combined with the collected IPD.
Through an illustration with 5 IPD trials in hypertension, which investigate to what extent
Iowering of systolic blood pressure and diastolic blood pressure contributed to cardiovascular
prevention, we demonstrated that the proposed method was much sirperior to the existing
meta-analysis methods in terms of the biases and the mean-square errors for estimator of the
within-trial interaction. Using the SIPD enables orre to apply any approaches for the IPD
meta-analysis, and could have a huge possibility,to produce novel findings (e.g. a flexible
trial design) which is never provided by the existing meta-analysis methods.
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1 Introduction
1.1 Backgrounds
In clinical evaluation processes, meta-analysis is a statistical methodology to synthesise results
of several trials for the purpose of quantitatively summa,rising the evidence expressed. as a
treatment efiect (e.g. mean treatment difierence for continuous outcomes). The fundamental
objectives of meta-analysis are to accumulate evidence from smaller trials and to increase
statistical po-u/er to detect an efiectiveness of a clinical treatment (Borenstein et at.,2009). For
example, when an investigator is looking for beneficial effects in specffic subgroups of patients,
a single trial may contain too few patients in the subgroup of interest to be informative. In
drug development, meta-analysis is recognised as a useful tool to summarise the overall
efficacy results of a drug application and to analyse less friquent outcomes in the overall
safety evaluation (Jones, 2008). Sutton and Higgins (2008) reviewed highlights of recent
developments in meta-analysis in medical research, and outlined how emphasis has been
placed on: heterogeneity and random-effects analyses, special consideration in difierent areas
of application, agsessing.bias within and across trials, extension of ideas to complex evidence
synthesis.
In clinical perspectives, there is a growing interest in extending meta-analysis beyond es-
timating an overall tieatment efiect, and to produce results tailored to the individual patient
or clinically relevant subgroups (Thompson and Higgins, 2005). Rubin (1990) has criticised
conventional meta-analysis techniques just averaging the treatment effects from each trial;
and has suggested a need to estimate the efiect of treatment versus control as a function of a
set of scientific factors that influence efficacy (e.g. age, race and gender). This requires meta:
analysis models that assess the association (or interaction) between iatient-Ievel covariates
and the statistical measure of interest. Meta-regression (MR) is a technique for modelling
relationships between the treatment effect and trial-level covariates, and also can be used
for assessing how the patient characteristics a.ffect the clinical efiectiveness in the context
of meta-analysis. The MR approach has been successfully applied with trial-level variables.
Berkey et aI. (L995) showed that the efficacy of BCG vaccine for tuberculosis increased with
distance of the trial site from the equator. Thompson (1993) demonstrated that cholesterol-
lowering drugs were more eflective in reducing ischemic heart disease in trials in which the
treatment groups achieved greater average reductions in serum cholesterol levels lelative.to
their respective control groups. However, most meta-analysis methods build models on ag-
gregate data (AD) obtained by summarising individual patient data (IPD) which should have
been measured originally in each trial, and thus a pooled treatment effect is estimated with
ignoring scheme of sampling IPD. For this reason, the MR model have often been criticised
(Thompson and Higgins ,2002; Riley et aL, 2010). The MR model incorporates covariates as
summary statistics on background factors of patients, such as a mean age and a proportion
of male patients in each trial. This foeans that the patient characteristics are evaluated ex-
pediently with trial-Igvel covariates in place of patient-level covariates. It causes a technical
issue that is referred to as ecological bias (Morgenstern, 1982), and leads to a limitation in
interpretation (Thompson and Higgins, 2002). In pa,rticula,r, it is well known that, for a
treatment-covariate interaction between a clinical treatment and a patient characteristic, a
test using the MR model has seriously lower statistical power than that using the lPD-based
model (Lambert et a1.,2002; Simmonds and Higgins,2007). Berlin et at. (2002) conducted
two types of meta-analyses by using individual patient-level data and trial-level data from 5
trials in their clinical research, and showed that the meta-analysis based on the trial-level data
failed to detect the treatment-covariate interaction. Thompson and Higgins (2002) advocated
that the relationship described by the MR model is an observational association, so this sufiers
from the bias by confounding. Note that the MR model assumes the (across-trial interaction'
between the treatment effect estimates and mean covariate values reflects the more pertinent
'within-trial interaction' between individual outcomes and individual cova^riate values. This
may not be true in practice, as across-trial associations are pron€ to trial-level confounding,
and may truly not reflect within-trial associations (Riley and Steyerberg, 2010).
As alternative solutions to this problems, some meta-analysis methods using IPD have
been suggested (Riley, Lambert and Abo-Zaid, 2010; Simmonds et a1.,2005). In these meth-
od.s, once the original IPD including patient-level outcome and covariate values are collected
from all trials involved, any flexible statistical approaches, such as multilevel models (Gold-
stein_ ef aI., 2000) and hierarchical random effect models (T\uner et a1.,2000; Whitehead
et a1.,2001; Higgins ef at., 200L; Riley ef al., 2007), are applied to the IPD. This brings
many opportullities over the AD approaches in the sense of der市ingS¨i"d Summary re―
suLs directtt cheCking mOdelling assumptions,and TSessing non-linear trends(RibL 2010).
Meta―nalysёs based on IPD a1low one to achieve much more meaningful evaluation on the
treatment―covttiate intOraCtion by separating lt into the across―trial and the within_trial e■
fect;in particularぅthe IPD met}analysis is an only way to assbss the within―trial inter ction
e■ct.However,the use of full IPD is not always without its difncuLie,。In pⅢticular,this
apprOach is resollrte inte■iVe, because substantial tilne and costs are required to contact
trial authors,to obtain theiI IPD,to input and clean the provided IPD,to reso市e y data
issues through dialog with the data providers,and to generate a consistent data fbrmat across
trials(Riley cι α ,2010).And also,practitioners cannot always colleCt the IPD from an trials
because the IPD Inight'have been lost or damaged,or trial authOrs may nOt be contactable
or willing to collaboratё.Ri ey cサal(2010)pOint,d Out that the possibility Of Collecting
the IPD frOm all trialS iS not so high.If the conectability of IPD is Tsociated with the
resuLs in each trial,a meta―analysis based oコけ On the collected IPD may be biased(St9W―
art and Tiernёy・ 2002). For this reasOn,it has become increasingly important tO cOnsider
situations where some trials prOvide IPD and the others provide Only AD.Some researcheリ
have already investigated lЮw to combine IPD and AD in meta―alysis,especially when
treatment―covariate interactbn is of interest(Riley cサαl,2008;Sutton,不endrick and Cou―
pland,2008;Riby and Steyerberg,2010).Such apploaches have嵐lso been develo ed in the
cottext of ecological study(Jackson,Best and Richardson,2008;Halleuse and Wake■eld,
2007;HaneuSe and ttrごb■ёld,2008;lVake■eld,2004;Wakefleld θι al,2011).Wake■eld ct
al(2011)adVOCated that the only reli¨b apprOachおr relllov ng eco16gicJ bias b to sup―
plement the eco10gical data with individual―le“l informat ono Jackson,Best and RichardsoIL
(2008)suggeSted Bayesian hierarchical Felated regression which uses Markov chain Monte
Carb method to simultaneOusly estimate IPD trials and AD t五als models hnked by common
parameters, where the IPE)supplelnent the aggregate information across diferent groups
such as geographical arёs,
n『。m these backgrounds,we propose a meta―analysis mOthod fOr eptimating both the
across―trial and the赫ithin_trial interaction e■bct.For the case that all trials provide only
AD,we■rst assume an IPD meta―analysis model intluding pttameters of t¨acr6ss‐trial
and the within―trial interactionb■ct,and then marginalise the denstty of IPD with respect
to missing IPD,which reqlllres an integration over a regon reStri,tёd by obSer d AD.This
process produces a likelihood for the AD available, and allows one to get information on
the within-trial interaction by meta-analysing several AD trials. The idea of marginalising
the IPD meta-analysis model is inspired from ecological inference, in which the relationships
between individual specific quantities are evaluated by using population-level data. In partic-
ular, Wakefield and Salway (2001) presented a statistical framework for ecological inference,
describing parametric models for binary response data that include within-aggregation vari-
ability of covariates, which is intended to reduce the ecological bias. We emphasise that the
within-trial interaction can be. approximately estimated by using this likelihpod even if only
the AD are available from each trial When some trials provide IPD and the others provide
only AD, the proposed method is simply extended to combine IPD and AD. There, the like-
lihood for parameters to be estimated is given by product of a likelihood for the IPD trials
and the marginal likelihood for the AD trials. This again allows one to get information on
the within-trial interaction from the AD trials. Note that the proposed method is applicable
when parameters to be estimated can be assumed as fixed effects; so that the treatment effect
and the treatment-covariate interaction effects are assumed to be common across trials.
As a breakthrough of the existing meta-analyses, we propose a meta-analysis method
based on simulated IPD (SIPD), which reconstructs the missing IPD for each trial and then
applies a standard IPD meta.analysis model to each SIPD. When some trials provide IPD and
the others provide only AD, the proposed method reconstructs the missing IPD for the AD
trials and then meta-analyse each set of SIPD combined with the collected IPD. We show,
once the SIPD are generated, how existing IPD meta-analysis apprqaches can be applied,
and we demonstrate the benefits of incorporating the SIPD. We here consider two types of
sampling procedures for generating the SIPD: frequentist and Bayesian procedures, which
are inspirgd by multiple imputation applied in the analysis of incomplete data with missing
outcomes and covariates (Rubin, 1937). In fhe frequentist procedure, each set of SIPD is
generated from a conditional distribution of the missing IPD given the AD (and the collected
IPD) and a known parameter, and then resulting estimates from each SIPD (combined with
the collected IPD) axe summarised by using Poor Man's Data Augmentation 2 proposed by
Wei and Tanner (1990). In the Bayesian proced.ure, each set of SIPD is generated from a
posterior predictive distribution of the missing IPD given the AD (and the collected IPD), and
then resulting estimates from each SIPD (combined with the collected IPD) a,re summarised
by using Rubin's (1932) rule. Both procedures ultimately produce a posterior distribution
of parameters of interest, and thus a posterior mean and variance for frequentist inference.
Since these approaches also use the scheme of marginalising the missing IPD, any advantages
Table I. Summary of the 5 trials in hypertension, included in the meta-analysis of Wang et
a/. (2005).
Number of patients
SBP
(fO110W‐μp―baseline)
Control Theatment Control Tfeatment Estimate of
mean mean meafl mean mean difrerence(s.d.) ('.d.) (..d.) (r.d.) (s.e.)
雌 s)
Thiaf
name* Control Tteatment
HEP
EWPHE
MRC-2
SHEP
Sy‐Eur
1337
2371
2297
69.57
(5。39)
74.11
(8.69)
70.43
(2.75)
71.54
(6.68)
(6.68)
69.71
(5.18)
72.64
(7.99)
70.39
(2,77)
71.64
(6.72)
70.25
(6.75)
-13.23
(2.39)
-12.68
(3.27)
-10.65
(0.85)
-11.51
(0.56)
-10.18
(0.46)
??
??
??． ?
????
????
???
?
?
??
-11.65    -24.88
(23.30) (21.11)
-7.78     =20.46
(22.76) (19.80)
-17.55    -28.20
(21.95) (21.78)
-13.88    -25.39
(19,90) (1842)
-8.70     -18.89
(15.04) (16.15)
SBP: systolic blood pressure, s.d.: standa,rd deviation, s.e.: standa,rd error
*l}ial names are consistent with Wang et al. (2005), where further details and trial publications
can be found.
provided above are held in these frameworks. F\rrthermore, using the SIPD enables one
to apply any approaches for the IPD meta-analysis, and could have a huge possibility to
produce novel findings (e.g. a flexible trial design) which is never provided by the existing
meta-analysis methods. Note that the proposed method is again applicable when parameters
to be estimated can be assumed as fixed effects.
1,.2 Motivating examples
L.2.1 Hypertension data
Wang et al. (2005) performed a quantitative overview of trials in hypertension to investigate
to what extent lowering of systolic blood pressure (SBP) and diastolic blood pressure con-
tributed to cardiovascular prevention. They selected randomised controlled trials that tested
active antihypertensive drugs against placebo or no treatment. For their analyses, IPD was
sought from trials in the Individual Data Analysis of Antihypertensive intervention trials
data set (Gueyffier et a1.,1995) or at the Studies Cooidinating Centre in Leuven (Lfu et al.,
1.998; Staessen ef al., L997; Amery et al., L985). 10 trials were ultimately included, and these
provided IPD for a total of 28,592 patients. To illustrate mdta-analysis methods introduced
in Chapter 2 and Chapter 3, we will ca"rry out a meta-analysis of 5 (12,603 patients) of these
L0 trials, which are sufficiently homogeneous across trials with respect to a treatment effect
and a trial-level cova,riate. These.5 trials were chosen as they were conducted in populations
with a similar mean age around 70. The mean change in SBP (follow-up minus baseline)
for each treatment group in each trial are shown in Table I, with negative values indicating
a beneficial effect. The treatment efiect is shown in the rightmost column in Table I, with
negative values indicating that the treatment is effective. Table I also shows the mean age,
and the groups appeax to be well balanced in each trial at baseline.
One of the usual way for displaying meta-analysis data is known as forest plot. Figure
1 shows the forest plot of the 5 trials in hypertension. The position of the black squares
represents the findings (an estimate of the mean outcome difference between groups, and
its standard error) from each individual trial. The size of the square is proportional to the
precision of the trial (roughly speaking, the sample,size). A horizontal line drawn on both
sides of the squa,res for each trial denotes the 95 per cent confidence interval of the treatment
effect estimate. A pooled treatment effect estimate obtained by combining all 5 trials is
displayed as a diamond in the lowest part of the forest plot. We here assume that all 5
trials share a common true value of the mean difierence (i.e. the fixed treatment efiect), and
we estimate the pooled treatment effect. Now let MDt, ffi; and Z(ffi;) be a true value
of the mean difference from the iih trial (i, : L,...,5), an estimate of MD; and a va.riance
mean MD; and
MD=l罐Dl=・…=1肛D5・
Then,the pooled mean diference is estimated by
?????????????????????．
???
?
?（????
倉品MD= =-10.77
を続
and the 95 per cent confidence interval for MD is given by
ffi + 1.e6 x (r **) -"' : [-11.40, -10.14].\;i v(MDi) /
These results (seen in Figure 1) indicate that the treatment is significantly effective in reducing
SBP by, on average, L0.77 mmHg more than placebo.
We also examine the extent of heterogeneity in the treatment effect across the 5 trials. It
is generally accepted that meta-analyses should assess heterogeneity, which may be defined
as the presence Of variation in true efect sizes underけg th diferent t di s(Higgins,
2008)。Cochran's c testお0乱en applied in meta―狙alysis for letermining whether there is
heterogeneity i■treatment efFects(COChran,1954).For the 5 triab in hypertension,the 9
test evahates a llull hypothesis HO:MD=vDl=・…=MD5 by uSing the followitt Q
statistic which has a chlsquare distribution with(the llumber of trials minus l)degrees of
■eedom:
°=と
,1平テ需語F半=4.849 γ χZ.
which provides a p-value of 0.303, and thus there is no strong evidence of heterogeneity.
F\rrthermore, .[2 index is the proportion of total variation in the estimates of treatment effect
that is due to heterogeneity across trials, and can easily be interpreted as a percentage of
heterogeneity (Higgins and Thompson, 2002). For the 5 trials in hypertension, 12 is given by
12=0・4×100=17.50 per cent.
菫ere,according to a tentatir Classi■Oation of」2 values with the pllrpose of helping to in―
terpret its magnitude by Higgills and Thompson(2002),the percentages of around 25 per
cent(」2=25),50 per cent(12=50),and 75 per cent(12=75)would mean bwi medium,
Trial name Mean Difference [ 95 per cent CI ]
(1・1)
HEP
EWPHE
MRC・2
SHEP
Sy―Eur
-
叫
智
-13.23 [‐17.91, ‐8.55]
…12.68[-19.08, ‐6.27]
‐10.65 [-12.31, ‐8.98]
‐11.51[-12.60, ‐10.42]
‐10.18 1-11.07: ‐9.29]
Sulmary
‥
‥
‥
?
-t0.t7 l-il.40, -10.14l
:
-20
:
-15
:
-10
‥
?
?
?
Mean Difference
Figure L. Forest plot of 5 trials in hypertension.
Th,ble II. Summary of the 5 trials in home safety education, included in the meta-analysis of
Sutton, Kendrick and Coupland (2008).
Intervention group Control group
No.of
trial* 飢辞:‰話馨龍躙 柵:‰熱留:ツ晰 Logtttrttb m靭鰍路鶏s
Tria1 1
■ia1 2
Tria1 3
■ia1 4
■ia1 5
28/49
76/85
25/57
408/742
250/363
25/47
70/89
16/55
328/718
239/360
0.16
(0.41)
0.83
(0.44)
0.64
(0.40)
0:37
(0・11)
0.11
(0.16)
?
?
?
?
?
?
?
?
?
?
?
?
?
?
?
?
?
?
?
?
?
?
?
?
?
?
?
s.e.: standard error.
*Ёach t五al is aalbitrarily numbered,diferehly■O  sutton,Kendrick and Couplarld(2008)
and high heterogeneity, respectively. Thus , the 12 value (1.1) again indicates poterrtial low
heterogeneity across the 5 trials. Therefore, we concluded that any models with fixed treat-
ment efiects, which are introduced in Chapter 2 and Chapter 3, could be appropriate for the
5 trials in hypertension.
It is also clinically important to assess how the age. adjusts the treatment efiect. The
hypertension data will be used in this paper to demonstrate and critically assess the methods
developed; those interested in more clinical conclusions axe referred elsewhere (W*tg et a!.,
2005).
1.2;2 ffome safety education data
Sutton, Kendrick and Coupland (2008) performed a systematic review to investigate the
efiectiveness of home safety education on the provision of a safety equipment. In pa,rticula,r,
they meta-analysed 8 trials (Clamp and Kendrick, 1998; Nansel et a1.,2002; McDonald ef a/.,
2005; Watson et a1.,2005; Kendrick et at.,2005; Kendrick et a1.,1999; Sznajder ef a1.,2003;
Gielen et a1.,2002), which have inspected whether an educational intervention increases the
ownership of stair gates installed for the prevention of falls in children. As a participant-level
socioeconomic characteristic a,ffecting the intervention effectiveness, they were interested in
whether the family is a single or two-pa,rent household; so that they assessed how the number
of families with a fitted stair gate in the intervention group is different between these two
participant subgroups. The review involved 6 trials (3,447 participants) with IPD and 2 other
trials (193 participants) with AD. And also, participants in 3 trials were allocated to some
clusters nepted within the trials. To illustrate meta-analysis methods introduced in Chapter
2 and Chapter 3, we here carry out a meta-analysis for 5 (2,565 participants) of 8 trials,
which are sufficiently homogeneous across trials with respect to a treatment efiect and a
trial-level covariate. Although pa"rticipants in one trial are allocated to 37 clusters, we ignore
this pa.rticipant-clustering to avoid further complexity. We focus 6n, gender of children as a
participant-level covariate, and mainly assess how gender afiects the intervention efiectiveness.
The number of participants in each group, and the number of participants with a stair gate
in each group are shown in Table II. The intervention efiects (log odds ratio between two
treatinent groups) from each trial are shown in Table II, with positive values indicating a
beneficial efiect. Table II also shows the proportion of male participants in each trial. There
is small variation in the proportion of male pa'rticipants across trials.
Figure 2 shows the forest plot of the 5 trials in home safety education. The position of
the black squares represents the findings of the log odds ratios from each individual trial.
Now let logORa, logG,j and V(log@; U" a true value of the log odds ratio from the
ith trial (i, : 1,. . . ,5), an estimate of log O& observed and a va,riance estimate of log@,
respectively. Assume that log@ is normally distributed with mean logOft and known
No.oftrial Odds Ratio [ 95 per cent CI ]
Tria1 1
Tria1 2
Tria1 3
Tria1 4
Tria1 5
申
:
―
1.17 [0.52, 2.62]
2.29 [0,97, 5.40]
1.90 [0.87, 4.16]
1.45 [1.18, 1.78]
1.12 [0.82, 1.53]
Sll―ary
‐
‐
‥
? 1.38[1.17,1.62]
0.3        1.0        3.0        9.0
0dds Ratio(10g scale)
Figure 2.ForeSt plol of the 5 trials in holne safety education.
variance y(10g OR),and
OR=ORl=…・=OR5・
Then,the pooled odds iatiO is estilnated by
???
?
?
?
?
?
?
?
?
?
二 1.38
倉耗轟奇
轟d the 95 per c6nt cOddence intervalぉr ott is giVen by
■ふ卸瞥愴鳥 )η邦¨
Th9Se results(seen in Figwe 2)i■diCates that the the intervention signincantly incFeases the
probabi“y Of OWnership Of the stair gate五〇re than 9ontrol on average.
We also examine the extent of hetёrogen i y in the treatment efbct across the 5 trials.
The C testきave a c statistic
O=丞豊量霧詮羨暴手
菫工=4.067～χZ.
and its p―value of o.397,and thus there is no strong evidence of heterogeneity. Further,12
index computёd in the same way for(1・1)WaS l.65 per cent.This again indicateS potential
low heterogellleity across the 5 trials. Therefore, we co■cluded that ixed treatment e■bc
models introduced in Chapter 2 and Chapter 3 could be appropriate ibr the 5 trials in home
safety educ¨ion.
It is abo chnically il■■portant to assess how gender ofchildren attustS the treatnlent efect:
The home safety education data will be used in this paper to domonStrate and critically assess
the met“os deVe10ped;those interested in more clinical∞nclllsiolls ar6 referred elsewhere
(SuttOn,Kendrick and Coupland,2008).
1.3 Components of this paper
In Chapter 2, we introduce IPD and AD in two situations where: (i) a single continuous
outcome and a single continuous covariate are observed from each patient, (ii) a single bina,ry
outcome and a single binary covariate are observed from each patient, and describe IPD
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meta-analysis models and the MR models for each situation, respectively. We also discuss
the difierences between the within-trial and the across-trial interaction. Through applications
to the hypertension data and the home safety education data, the methods are illustrated.
F\rrthermore, for the case that some trials provi.de IPD and the others provide only AD,
we describe existing models for combining IPD and AD. In Chapter 3, re describe our
new rneta-analysis method with marginalising the missing IPD for the situation (i). The
method is extended to combine IPD and AD. We also describe meta-analysis methods based
on simulated IPD. The methods a,re explained by frequentist and Bayesian perspectives,
and applied to both situations (i) and (ii). In Chapter 4, we conduct simulation studies
to examine the performance of the proposed method with marginalising the missing IPD in
comparison to existing methods. F\rrthermore, another simulation study and an application
to the hypertension data are conducted to assess the benefit of using simulated IPD. Finally,
in Chapter 5, we conclude this paper with some discussion.

2 Ii',xisting methods
Consider a meta-analysis of If trials in which patients are assigned to either a treatment group
(T) or a control group (C). Let r4 be the number of patients in the ith trial (f : 1, . . . , N),
n41 and nigbe the numberp of patients for the treatment and the control group, respectively.
Here, let U6 and z,ii be a patient-level outcome and covariate observed from the jth patient
(i : L, . . . ,n.i) in the ith trial, and let r,ii be coded 0/1 to denote control/treatment group.
We here describe some existing meta-analysis methods for two data situations (continuous
outcome and covariate, and binary outcome and covariate). We also consider the case for
mixture IPD and AD.
2.L Continuous outcome and covariate
Let yii and. z6i denote a continuous outcome and a continuous covariate value from the jth
patient in the ith trial. If just meta-analysing the IPD; i.e. (Ati, *ti , z';) for i : L,. . . , If and
j : L,. ..trli,tRiley et a/. (2008) proposed the following one-stage model that accounts for the
clustering of patients within trials by a trial-specific intercept (d,;,), and estimates a pooled
treatment-covariate interaction (.yry) based on within-trial information separated from the
across-trial interaction (7a) :
ν″=φづ+θ″″+μz″+γA″ 為+η″ηバZリ ぅー)十C″,
妨～N(0,弓),
ノ=1,・・,πづ;に1,・..;Ⅳ。 :
(2.1)
Here, Q6 is the fixed intercept for the ith trial (which essentially accounts for clustering of
patients within trials), d is a fixed hypothetical treatment efiect in a trial with 2i: 0, l.r is
a mealr change incontrol group outcome for a one-unit increase in z;i,7a and 7ry are the
across-trial and the within-trial effect of treatment-covariate interaction, respectively, and
h:D?Lrzejlu denotes a mean covariate in the ith triat. Note that, g, p,'YA and 1y
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are tFeated as tted e■cts h re, and σtt is aSSulned to be collnllnon across trials. In contrast
to Riby ct al oooO,II10de1 0・⇒ⅢhdeS a comllnon μ and弓“losS trttb rather than
at五alspedicルをand弓ルr the jth t五J,These assumptbnp are necesstty,o bJd the
proposed method(See chapter 3)。According to a recommendation by Riley θサαl(2008),
the treatment―covariate interaction is separated into the across―trial and the within…trial
efFect.This separation is clinically important to avoid making a wlong conclusion about the
treatlnent‐covariate intёraction,■hich might occw if wrOngly amalgamating the across―trial
and the within―trial e■cts(Riley and Steyerberg,2010)。One should pay attentiOn to the
fact that the across‐tri l relatioIIships can be very diferent from the within―trial elations■ps
due to ecological bia7s and/or tria■level confounding(RileL Lambert and Abo―Zaid,201o)。
This modelling framework is also discussed in the context of regression analysls of clustered
data(Neuhaus and Kalb■eisch,1998;Begg and Parides,2003)。         1
1n general meta―analytic sttuations,we observe only the AD iom each trial,rather than
the IPD■ollll each patient.Here,the AD consist of sample means and sample variances for
ind市idual obs∝vatbns in each group and t五aL i.e。し T,β:づT,aT,SZづT,動し,s;じc,らc,S%c)bF
づ=1,…。,Ⅳ,where
"=¥,
伽 =¥,
島ぼ=  ,勿圭¥ぅ
もc=  ,羅雫 ,
嗚〒y(硫)=慨島肝:;づ
多二    :
-2 
-Di.r?ni - 
zt)2
D zi.T niT _ 1, ,.
^2 
-Ei."Qoi - 2rc)2DziC 
- n;(,. _'I
Then, an MR model can be applied to the AD as follows:
αづ=α+βλ+6づ,
6づ～N(0,σ務),
づ=1,…。,Ⅳ.
Here,α″千働T―ac denotes a mean outcome diference
alld the error variance is assumed to be klllown as
between groups from the ath trial,
(2.助
where
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If we assumu zi,i : Ze in model (2.1) with trial-specific error variances, we have
νり=φづ十θ″″十μλ+γA″″乾十(″,
c″～N(0,イづ),
ブ=1,・,ηづ;づ=1,….,Ⅳ.
(2.3)
When first taking an average of both sides in model (2.3) for each group and trial, and
subtracting the average of the control group from that of the treatment group for each trial,
a model for the mean outcome differences between groups can be derived as follows:
Q～N←鑽 →
ι=1,….,Ⅳ
where弓じis eStimateo by t=SL・ThiS model has the same form as the representation of
the MR model(2.2);so that,under an assumptiOn of物=れ,θ and tt in model(2・1)are
equivalent to α and β in the MR model(2.2),respectivett ThiS means that the MR hodel
(2.2)giveS a restrictive result abOut the across―trial relationships under a condition that
variation of the covariate is equal to zeroo IIowever,we have more interest in the parametOr
of 7、、「,which represents an increase in the treatment efFect according to One-1lnit incre■e in
the patient―l rl COVariate zかThus,if We intend tO estimateっ、v by llsing he estimate of‐
β,thiS might lead to an incorrect conchsion for the treatment―covariate interactiono When
the number of trials and variation ofぇcFoss tri41s are sma11,due to the ecological bias,the
statistical power of β beCOllllles much lower thall those of ttv(Simmons and Higgins,2007).
Application to hypertensi6n dath
C6nsider the hyperteTion data,and we now demollStrate how age moditt the treatllnent
efFect on change in SBP(blbW―up minus baseline)。Fitting model(2.1)to the IPD ttom the
5 trials,estimateS Of each parameter in model(2.1)were θ=31.95(s.e.=32.83 and p¨value
=0.273),ル=0・035(s`e.=0・039 and p―value=0.370),今A=~0・662(soe.=0・464 and
p―vahё=0。154)attdれv=0・087(soe.=0・055血dp―value=0.114),respectivett F“ting
the MR Inodel(2.2)to the本D ttom the 5 trials,estimates Of each pttametёr in model(2.2)
were a=43.13(s.e.=32.94 and p「value=0。188)and β=―a766(s.e.=0。466 and p―value
=0.100),reSpectivev The across‐trial r l tion hips(θ a dメ江)Obtaillled by■tting model
(2.1)were similar to thoseいnd β)Obtained by itting the MR model(2.2).A slig“
diference between θ and a(orttA and β)iS due to model assumptiolls;SO that the MR model
(2.2)assumes knowtt error vttiante。(σ務)fOreach trial while model(2.1)・aSSimes a tommon
error variante(弓) croSS triab,and θ and tt are arected byルand ttw・The across―trial
rёlationships had much larger standard errors in comparison with those of the witttll―trial
relationships(ルandれv)・As for the treathent―cOvariate interaction,the across―trial efect
was substantially diferent from the within―trial e■ct on the point estimates.ThiS ShOWS
the importance of separating the within―t ial in eraction from the acrOss=trial interaction,
MeanAge
Figure 3. Scatter plot for the 5 trials in hypertension with across-trial and within-trial
interaction effect estimates, in which:
o A solid line represents the across-trial interaction (7a) between mean age (z;) and treatment
efiect estimated by fitting model (2.2).
o Dashed lines represents the within-trial interaction (7ry) between age and treatment effect
estimated separately within each trial using IPD and model (2.1) without 7a.
o The gradient ofeach dashed line indicates the change in treatment effect for a one year increase
in age within each trial.
o The width of the dashed line about the centre of each circle is defined bv 1 times the standard
deviation of age in each trial.
o Each circle represents a trial and is centered at Zrineach trial; the circle size is proportional to
the sample size in each trial.
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as chance, confounding and/or ecological bias is causing the across-trial effect to act in the
opposite direction of the within-trial effect here. If we used a model without separation of the
across-trial and the within-trial interaction, we'would get a potentially wrongly amalgamated
result on the interaction between treatment and age. The standard error of fa was also much
la,rger than that of iw, because the number of trials was small and the mean ages were fairly
homogeneous across the 5 trials. There was no observed between-trial heterogeneity in the
within-trial interactio n (12 :0%), and thus the fixed efiect assumption is also plausible for
this parameter. Figure 3 also shows this difierence between 'ya and 'yyy; the within-trial
interaction (dashed lines) have aknost flat gradients, especially in the larger trials, while the
across-trial interaction (solid line) has a steep negative gradient. It highlights pitfall of using
ie to make inferences about iry, that is, ecological bias and confounding.
2.1,.1 The case for mixture of IPD and AD
Consider a meta-analysis of .lf' trials which consist of lf trials providing AD (AD trials)
and -l['- N trials providing IPD (IPD trials). The IPD trials provide the patient-specific
observation s; i.e. (y,;irfiij, zij) fori, : N + L, . . . , ff' and j - 1, . . . , n';. When a mixture of
IPD and AD trials are available, model (2.1) must be modified to combined IPD and AD. The
simplest solution is to reduce the collected IPD to AD and treat all the data as AD, so that
any information on the individual-level associations from the IPD trials is lost. Alternately,
one could use only the collected IPD, so that available information from the AD trials is
thrown away. In contrast, Riley ef a/. (2008) proposed a model for combing IPD and AD,
which simultaneously estimates the within-trial relationships (using just the IPD trials) and
the across-trial relationships (using both IPD and AD trials). All these approaches are now
.:
described.
Meta-regression model that uses only AD frorn all trials
Once the IPD for trials i : .l/* 1,...,-ly''are summarised to the AD, the MR model (2.2)
canbeappliedtotheADfor.alltrialsi:1,...,N,.
Model that uses only IPD trials available
If one uses only the collected IPD, model (2.1) can be applied to the IPD from trials 'i :
-nf + 1,...,N'. When the number of IPD trials is o4e (i.e. -lf' : lf + 1), model (2.1) is
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Inodifled as follows:
.    
νヴ=φづ+θ″″十μZ″+γw■″1句―る)+ι″,       (2.4)
cあ～N(0,イ),
ノ=1,・..,ηづ;づ=Ⅳ・
This is becallse one cannot estilnate the across―trial nteractionっ
`A With a single trial.
Modelthat uses both IPD and AD trials
The model for combining IPD and AD proposed by Riley θι αl(2008)is as fO110ws:
Uii : D6Qa * 0r6i -f D6pzii * Jari726 * D,;7ysr5i(zit - z6) + eii, ●・→
cぁ～N(0,Ll)
where D`is a dummy variable to distinguish IPD trials■m AD trial . For the dth IPD
tri」(づ 基 Ⅳ +1,…,Ⅳ′),Dづ=1,場=吻,L*≡b;and場=物・ For the dth Aうtrial
(づ=1,…・,Ⅳ),there is only one outcomё(J〒1)and Dぅ=0,″を1=1,υ左=硫,レT=y(銑)
aSSu■9dkWn,and場=島。MOdel(2.5)ensures thtt the AD士om trials j=1,…,Ⅳ
help to estimate only the across―trial r ltti llships(θ and γA),Whereas the IPD ttom trials
づ=Ⅳ+1,…。,Ⅳ′help to estimate an the parameters.That is,only the collected IPD
contributes to the estimation of the within―trial relationsh ps(μ and ttv)。As in hodel(2。1),
we again assume thtt θ,μ tt andγw are&ed efFeёts,狙d tt iS COmmon across tria卜.
Application to hypertension data
Co“ider agai■the hypertension data,and tt now demollstrate how age modify the treatnlent
erect on change in SBP(f0110W―up minus basehne)in the Case that some trials pro宙de IPD
alld the others provide only ADo To imitate situttiott invo市ing IPD for some trials a■d only
ADおr other、we genertted scenarios where only a limttё4血mber f triaゃ(,Om lt0 4 of
the 5 triab)prOvided lPD,and the other trials jllst provided AD as presented in Ъbb I,
which is typical of the AD available to meta―analysts in practice.In each scenario:We carried
out analyses by:(i)■tting the MR model(2.2)to AD iom a■5 trials,(ii)■tt ng model(2.1)
or(2.4)to IPD ttom only IPD tiials available,(ili)■tting IIlodel(2.5)to the m破t lre ofIPD
and AD ttom a11 5 trialso ln both parts(ii)and(iii),the analyses weFe run for each possible
combination of IPD and AD trials. For example,in the scenario that 2 trials provide IPD
(1.e.2 1PD trials and 3 AD trials),we performed 10 analyses,olle for each combination of
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which 2 trials provide IPD and 3 provide AD. In each scenario, we compared the results with
those from,a meta-analysis of IPD from all 5 trials (i.e. full IPD analysis), allowing us to
empirically assess the performance of each method and identify the value.of combining IPD
and AD in practice
The results by each method are shown in Table III. Fitting the MR model (2.2) to the
AD for all 5 trials naturally provided results only of the across-trial relationships (o and
B), whose estimates and standard errors were close to those of 0 and 74 from the full IPD
analysis. Fitting model (2.1) or Q.Q to only available IPD provided both of the results for
the within-trial and across-trial relationships. Estimates of 'yyy and their standard errors got
close to those from the full IPD analysis rapidly as the proportion of trials providing IPD
increasedl however, estimates of 74 differed seriously from those from the full IPD analysis
with huge standard errors, especially in the case of small proportion of IPD trials.
The strategy of combining IPD and AD by fitting model (2.5) allowed us to not only get
more accurate results for the across-trial relationships but also evaluate on the within-trial
relationships with a certain degree of precision. Including AD trials remarkably improved
the precision of estimates for the across-trial relationships in comparison with analyses by
using only the collected IPD. It was also confirmed that model (2.5) correctly allowed only
the IPD trials to estimate p and 7qr. This explains why the standa,rd errors of '6ry increase
as the proportion of IPD trials decreases and emphasises why it is better to obtain IPD from
all trials.
2.2 Binary outcome and covariate
We now suppose that a single binary outcome variable Y and a single binary covariate Z arc
observed for each patient in each trial. Let Ati and zii be a binary outcome and a bina,ry
covariate value for the jth patient (i : L,. . . ,ni) in the ith trial.
If just meta-analysing the lPD; i.e. (Ati,*ti,zii) foyi:1,...,-ltr and i - 1,.. .)n'i) orre
can use the following one-stage model that accounts for the clustering of patients by a trial-
specif,c efiect ({;), and estimates a pooled treatment-covariate interaction (7tltr) based on
within-trial information separated from the across-trial interaction (7a):
ν″～Bernotlli(g″),
bg丁皇篭赫
=φOす仇十θ″弯+μz″十,AZ″屁十γw物1句=島ゝ
ノ=1,…,ηづ;t=1,ハ。IV.
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(2.6)
Table II[. Average of estimates and their standard errors for each parameter when analysing
change in SBP (follow-up minus baseline) from the hypertension data, where estimates are
averaged across all combinations of IPD trials.
Average of
estimate
Number of trials  Only―  Mode
pro宙ding IPDキ  IPD  (2.5)
Average of
standard error
Only‐ MOdel
IPD   (2.5)
Hypothetical
treatment
effect 0
5/5*
4/5
3/5
2/5
1/5
0/5+
35.95
29.40    43.39
3.29    43.34
-31.55   43.56
-11.86   44.45
‐      43.41
32.83
41.77   33.10
65.05   32.75
129.2   32.89
1. 80   32.85
‐     32.94
Covariate
efiect pt,
5/5*
4/5
3/5
2/5
1/5
0.035
0.027    0.027
-0.017 -0.018
-0.117 -0.117
-0.311  -0:303
0.039
0.045   0.045
0.059   0.059
0.091   0.091
0.176   0.175
Across-trial
interaction
effect .ye
5/5・
4/5
3/5
2/5
1/5
0/5†
-0.662
-0.569 -0.766
-0.199  =0.766
0.293   -0.768
NA  -0,781
‐   -0.766
0.464
0.590   0.468
0.920   0.463
1=831   0.464
NA    O.464
-     0.466
Within-trial
interaction
efiect ,yp
5/5*
4/5
3/5
2/1
1/5
0.087
0.092    0.091
0.116    0.117
0.165    0.166
0.252    0.244
0.055
0.063   0.063
0.084   0.084
0.131   0.130
0.259   0.258
Only―IPD:Fit model(2.1)or(2.4)to only the collected IPD.
Model(2.5):Fit model(2.5)to the mixture ofIPD and AD.
・Results by ttting modёl(211)to the full lPD iom a11 5 trials.
†Results by ntting the MR mOdel(2.2)to the AD ttom a11 5 trials,
‡The numbers of combinatio■s of tri ls providing IPD are 5,10,10 and 5
in the scenarios of l,2,3血d41PD trials,respectively.
NA:Not available
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Ilere, Bernoulli(qar') represents a random variable following Bernoulli distribution with proba-
bility q;7, /s is a fixed interc ept, dt is the fixed effect for the ith trial, 0 is a fixed hypothetical
treatment effect in a trial with'Za:0, lr is a log odds ratio between cova,riate subgroups in
control group, 7a and Tw are the across-trial and the within-trial interaction efiect respec-
tively. This modelling framework were proposed by Riley and Steyerberg (2010) in the case
of binary outcomes with a single group. Note that, as in model (2.1), 0, p,'yA and'yy,' are
In general meta-analytic situations, we observe only the AD from each trial, rather than
the IPD from each patient. Here, the AD consist of the grouped forms of outcome and
covariatel i.e. (n6ar'tTriTtrlictmrcr*t) where ?iT (or rz;6) is the number of patients assigned
to treatment (or control) group in the ith trial, m6a (or rn;6) is the number of patients with
Y : L innla (or n16) patients, and 2i: Di\ zU lnn is the proportion of patients with Z : I
in the fth trial. Then, an MR model which has the same form as model (2.2) canbe applied
to the AD, where
銑=10g
mn(nrc 
- 
rnic)
mec(nt 
- 
mar)
and
弓づ=yl)〒赤 +:慕現 T十栽 +万蔦戸≡扇扇「
As another approach for nletttanalysing the AD,we here consider to partially recreate a
bi■ary data form ofIPD from the groupe4 fOrm ofAD,where patients with y=l or y=0
in each group are represeⅢed by a s ries of ones or zeros(RIゃy・SimmOnds and Look,2007).
h partitular,(πじた,mづん)forづ=1,…。,Ⅳ andんc{T,C),Whereたis a group indicator that
takes a value of T for tttatment 6r C for contr61,証e rewritten as(物ル″)おrづ=1,…,″
and′=1,…。,η
`。
Since tt is impossible to recreate the patient‐level covariates dhectly ttom
the:ADi the infOrmation 6f covariate is limited to tt for each trial.The■,one catt use he
following modeL
ν″～Bernoulli(g″), I
log Tモ争t7==φO+φづ+:″+γA"″ら,
づ=1,…。,Ⅳ.
0。つ
Thompson, T\rrner and Warn (2001) suggested that this direct modelling would be appropri-
ate in comparison to using the ordinary MR model where the log odds ratio estimated from
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each trial are assumed to be normally distributed with known variances, especially when the
observed event probabilities in a particular trial are close to 0 or L, and where the sample
size in each trial is small.
Application to home safety education data
Consider the home safety education data, and we now demonstrate how gender of children
modifies the intervention effect on the provision of a stair gate. Fitting model (2.6) to the IPD
from the 5 trials, estimates of each parameter in model (2.6) were A :7.184 (s.e. : 4.300 and
pvalue : 0.095), lr:0.07L (r.". - 0.1-L6 and p-value: 0.541), ia : -13.3L (s.e. : 8.343 and
---G--
0.49      0.50      0.51
Proportion ofMale Patients
Figure 4. Scatter plot for the 5 trials in home safety education with across-trial and
within-trial interaction effect estimates. in which:
o A solid line represents the across-trial interaction (7a) between the proportion ofmale patients
(z;) and. intervention effect estimated by model (2.7).
o Dashed lines represents the within-trial interaction (1p) between gender of children and inter-
vention efiect estimated separately within each trial using IPD and model (2.6) without 7a.
o The gradient of each dashed line indicates the change in intervention effect from females to
males within each trial; the length of the dashed lines is unimportant and is kept the sa,rne for
each simply to aid clarity.
o Eaclr circle represents a trial and is centered at 2t i;n each trial; the circle size is proportional to
the sample size in each trial.
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p-value : 0.111) and 'yry : 
-0.212 (..". - 0.165 and p-value : 0.199), respectively. Fitting
model (2.7) to the AD from the 5 trials, estimates of each parameter in model (2.7) were
0:7.L76 (r.". 
- 
4.299 and p-value:0.095) and'ya : 
-13.30 (s.e. : 8.341 and p-value:
O.ttf;, respectively. The across-trial interaction was substantially different from the within-
trial interaction on the point estimates. As suggested in the application to the hypertension
data, this shows the importance of separating the treatment-covariate interaction. If we used
a model without separation of the across-trial and the within-trial interaction, we would get a
potentially wrongly amalgamated result on the interaction between intervention and gender.
The stanilard error of 7a was also much lalger than that of iw, because the number of trials
was small and the proportion of male participants were fairly homogeneous across the 5 trials.
Figure 4 also shows this difference between f6 and "1y,'; the within-trial interaction (dashed
lines) have almost flat gradients, where the across-trial interaction (solid line) has a steep
negative gradient. It highlights the pitfall of using la to make inferences about fry, that is,
ecological bias and confounding
2:2.1 The case for mixture of IPD and AD
Consider the same case supposed in Chapter 2.1.1"; i.e. a meta-analysis of the mixture of I/
AD trials and N' 
- 
N IPD trials. When a mixture of IPD and AD trials are available, model
(2.6) must be modified to combine IPD and AD. As mentioned in Chapter 2.1.1, simple
solutions are to deal all the data as AD, or to use only the collected IPD. In contrast, Riley
and Steyerberg (2010) proposed a model for combing IPD and AD. All these approaches are
now described.
Model that uses only AD trials
Once the IPD for trials i : -lf * 1, . . . ,.ly'' are summarised to the AD, model (2.7) can be
applied to the AD for all trials 'i = I,. . . , N'.
Model that uses only IPD trials available
If one uses only the collected IPD, model (2.6) can be applied to the IPD from trials i
.nf +1,...,ff'. When the number of IPD trials is one (i.e. N' : lf +1), model (2.6)
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Hlodifled as fonow:
物 ～BernOulli(物),
10g T皇篭万1lo+仇+θ″″すμZ″+ηⅣIバ
`笏
-2)
プ=1,…。,πづ;づ=Ⅳ・
Model that uses both IPE)and AD trials
00
The model for combining IPD and AD proposed by Riley and Steyerberg (2010) is as follows:
anj - Berno,rlli(q,ri), (2.鋤
bg #qrJ = do * dt * Lrii * Dit"r,zi5 t 16r6iz6 * D,nsr.iQni - zr)
where Di is adummy variable to distinguish IPD trials (D; : 1) from AD trials (Dt: O),
and (Atitra) for the AD trials z : 1,.;., N are recreated from (n61r,m.yr) for /c e {T, C} by
the same way described above. As in model (2.5), Model (2.9) ensures that the AD from
trials i 
- 
1,,...,N help to estimate only the across-triai relationships (d and ?R), whereas
the IPD from trials i,: N * 1,..., N' help to estimate all the parameters. We again assume
that 0, pt,1s and.7W are fixed effects.
Application to home education data
Consider again the home safety education data, and we now demonstrate how gender of
children modifies the intervention efiect on the provision of the stair gate in the case that
some trials provide IPD and the others provide only AD. To imitate situations involving IPD
for some trials and only AD for others, we generated scenarios in the same manner as. the
application to the hypertension data; i.e. we assumed that only a limited number of trials
(from L to 4 of the 5 trials) provided IPD and the other trials just provided AD as presented
in Table II. In each scenario, we carried out analyses by: (i) fitting model (2.7) to AD from
all 5 trials, (ii) fitting model (2.6) or (2.S) to IPD from only IPD trials available, (iii) fitting
model (2.9) to the mixture of IPD and AD from all 5 trials. In both parts (ii) to (iii), the
analyses \rvere run for each possible combination of IPD and AD trials. I4 each scenario, we
compared the results with those from a meta-analysis of IPD from all 5 trials.
The results by each method are shown in Table IV. Fitting model (2.7) tothe AD for all
5 trials naturally provided results only of the across-trial relationships. Fitting model (2.6)
or (2.8) to only available IPD provided both of the results for the within-trial and across-trial
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relationships. By the similar trend shown Table III, estimates of "yq,' and'their standard errors
got close to those from the full IPD analysis rapidly as the proportion of trials providing IPD
increased; hciwever, the estimates of 7s difiered seriously from those from the full IPD analysis
with huge standard errors especially in the case of small proportion of IPD trials.
As in the application to the hypertension data, the strategy of combining IPD and AD
by fitting model (2.9) improved the precision of estimates for the across-trial relationships in
comparison with analyses by using only the collected IPD. It was also confirmed that model
(2.9) correctly allowed only the IPD trials to estimate p and 1ar.
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Th,ble IV. Average of estimates and their standard errors-for each parameter when analysing
the home safety education data, where estimates are averaged across all combinations of
IPD trials.
Average of
estimate
Average of
standard error
Number of trials  Only―  Mode1   0nly― Model
pro宙ding IPD‡   IPD   (2.9)    IPD  (2.9)
Hypothetical
treatment
efrect 0
5/5.
415
3/5
2/5
t/5
o/st
7.184
7.321    7.179
8.253    7.171
-7.953   7.155
0.420    7.223
-      7.176
4.300
5.010   4.300
7.179   4.301
58.90   4.302
0.307   4.315
-     4.299
Covariate
eftect p,
5/5Ⅲ
4/5
3/5
2/5
1/5
0.071
0,082    0:081
0,076    0.075
0.045    0.041
-0.042  -0.056
0.116
0.135   0.135
0.170   0:169
0.239   0.239
0.424   0.424
Across-trial
interaction
effect 7e
5/5.
4/5
3/5
2/5
t/5
o/st
-13.31
-13.60  -13.30
-15.46  -13.29
17.96   -13.26
NA  -13.39
 ¨     ―-13.31
8.343
9,726   8.344
13.99   8.345
120.5   8.347
NA    8.371
‐     8.343
Withill―trial
interaction
e,Ct神
5/51
4/5
3/5
2/5
1/5
-0.212
-0.225  -0.225
-0.218 -0.218
-0.178  -0.176
-0.048  -0.041
0.165
0.192   0.192
0.242   0.242
0.343   0.344
0.615   0,614
Only‐IPD:Fit model(2.6)or(2.8)to only the collected IPD.      .
Mo1¨(2.9):Fit model(2.9)tO the mixtuFe ofIPD and AD.
ホResults by ntting model(2.6)to the full IPD ttom a11 5 trials.
十Results by 6にting mOdel(2.7)to the AD ttёm al1 5 trials.
‡The numbeFS Of COmbinations of trials pro宙d ng IPI)atre 5,10,10 and 5
in the scenarios of l,2,3 alld 4 1PD trialS,respective与
NA:Not avallable
?
?
?
?
3 Proposed methods
3.1- Meta-analysis with marginalising the missing IPD
A structural Iimitation of the MR model (2.2) and,model (2.7) is that their inferential objec-
tives are restricted to the across-trial relationships (the hypothetical treatment effect and the
across-trial interaction effect). As illustrated in Chapter 2, the across-trial relationships are
prone to trial-level confounding and often sufier from large standard error, in compa,rison with
the within-trial relationships (the covariate effect and the within-trial interaction effect). We
now introduce a meta-analysis method for estimating not only the across-trial relationships
but also the within-trial relationships when all trials provide only AD..The proposed method
is simply extended to the case that som,e trials provide IPD and the others provide only AD
(i.". to combine IPD and AD). We here suppose the situation where a single continuous
outcome and a single continuous covariate are observed from each patient in each trial.
3.1.1 Thd case for only AD
Consider a meta-analysis of .l[ trials which provide only AD. Original IPD which have been
observed in each trial can be regarded as missing data. We first assume the following IPD
meta-analysis model to the missing IPD:
νを=φづ+θ″″十μZ″+γA″″λ+つ、v“″(Z″―乙)十C″,
c″～N(o,イ),
J=1,・・1,ηを;に1,・.`,Ⅳ
0・⇒
where(aT,SLT,2T,S'づT,動c,SLc,乃S'ぅc)are aVailable for theづth trial,in place of thё
patient―speciflc observatiolls(物,″″,物)fOr J=1,…。,21・Then,we cannot obtain maXimum
likehhood estimateS(MLEs)of parameters of interest d±9ctly t om(3.1)for th  reason that
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each trial provides only AD. Indeed, sufficient statistics for model (3.1) a,re given by
Σめ,Σ蝙,Σ物,Σ場,Σ物物,
′∈T     ′こT     ′∈T ′∈T    J∈T
Σ物,Σ4,Σ物,Σる,Σ物物
′CC     ′∈C     ′∈C     プCC     ′∈C
おrづ=1,….,Ⅳ;whib ΣたT物物and ΣJとc物物are llot available.  :
To estimate the parameters included in model(3.1)by llSing only AD,the covariates
of patients assigned to the treatment(or COntrol)grOup in theづth rial are assumed to be
independent and identically distributed normal random va五ables with he nπzづT(Or πz`c)
alld variance ttT(Or ttc);i・e・
(3.2)
Here, Z; : \\ zU /ne is considered to be constant, and pa,rameters included in the covariate
distribution (3.2) are estimated by
焼 zづT=為T, ∂銑T=s,`T, 力zoc=屁c; ∂:づc=s:づc (3。3)
for i : 1, . . . ,.1f. If we also assume that zii and eii are independent of each other, we have
the following conditional distribution of yli given z1i:
(
arilz,i ru { *tt' + e + Qt + rw)zu+ (r'q - 1v7)z';'ol)' i eTIN(d,+t'zti,o)), j,-c (3'4)
And then, marginalising the joint distribution of (Atj,z;) withrespect to z;i,we have the
following marginal distribution of y6i:
Z″ ―
 {‖|11:::ILt:|| :[i: 
・
響～{‖III;::|::::|| ;[:
where
πνうT=φう+θ+μttzづT+γヽ島+っ～v(仇zづT―為),
弓づT=し■柿)資考″T+弓
鶴νac〒α+μπzづc,
弓づc=μ2場c+弓。
(3.5)
(3.6)
and
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(3。つ
Therebr%a loまhbtthood hnctbn br the paralneters OL.…,φⅣ,θ,μ,ぃ,御,弓)hCluded
in lnodel(3.1)is g市en by
編=増ト
鶴c{ac_にあ滋の2年sac}
μ?ひZic+σ多 0劫
―%づT bg((μ+7w)2∂:づT+1分一πac bg(μ2∂易c十弓)].
A remarkable aslect Of using the log―likel hood(3.8)is that the correlatitt between tt and
窃 are replaced with the correlation betwee五働T and ttzづT,or ttc and ttzづco Since we canllot
tOmpute MLEs ofthe parameters iom ttt log_likelihood(3.8)in a c10Sed―form,it is llecessary
to llse an iter■ive nl17neriCalこoll■puting algorithm such as Newton―Raphson method.
3.1.2 The case ibr lnixture of IPI)and AD
Consider the meta―analysis of Ⅳ′tiials which consist of Ⅳ AD trials and Ⅳ′―Ⅳ IPD trials.
As in Chapter 3。1.1,we■rst assume the IPD meta―analysis model to the collected IPD and
the missing IPD;i:e.
uu,: dt * |rai * pztj * 1sr6i26 * yvsr,iiQii - 2,i) * eii, 0・0
c″～N(0,イ),
J=1,・・・,ηじ;に1,・..,Ⅳ′
whereしT,sLT,2T,S:`T,働c,S;づc,効c SZづc)brづ=1,…・,Ⅳ and(物,″″,物)fOrづ=Ⅳ+
1,….,Ⅳ′andノ=1,…・,売
`are available.Becttse all trials tte independent of each other,a
bg―likelihood for the parameteis inchded in model(3.9)can be d“ived.as suttmation 9fthe
log五¨kelihood for the AD trials and that for the IPD trials.The forllller is already given by
(3.8),and the latter is simpけgiven by using the normal dellsitbs as bllowぶ
JIPD=
:づ圭 1を
← 魔 づ
―身
2摯二九Tθ″″~均~筆場あ―御″″摯 ―劾島・
Then,we can estimtte the pttattterS OL…っφNちθ,μぃ ,御,弓)hdu4ёd h IIl10dd oo
by maximising the log―■kehho d
ho * lpn
with respect to the parameters.
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3.2 Meta-analysis based on simulated IPD
Subsequentlg we introduce meta-analysis methods based on simulated IPD (SIPD), in which
the missing IPD are reconstructed by using the scheme of marginalising the missing IPD. For
the case that all trials provide only AD, the proposed method takes the following procedures
for inference of parameters.
For the case that all trials provide only AD:
(1) Generate multiple sets of SIPD for each trial.
(2) Fit an IPD meta-analysis model to each set of SIPD.
(3) Suitably summarise resulting estimates from the set of meta-analyses from Step (2).
We refer to these whole estimating processes as SIPD method. Figure 5 shows a flow diagram
of the SIPD method. Furthermore, for the case that some trials provide IPD and the others
provide only AD, the proposed method is extended to combine IPD and AD.
For the case that some trials provide IPD and the others provide only AD:
(1) Generate multiple sets of SIPD for each trial providing only AD.
(2) Fit an IPD meta-analysis model to each set of SIPD combined with the collected IPD.
(3) Suitably summarise resulting estimates from the set of meta-analyses from Step (2).
STEP(1)
Modeling and sillllllation
STEP(2)
An けs ng
STEP(3)
Sllmmarising
Figure 5. Flow diagram of SIPD method.
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STEP (1)
Modeling and simulation
srEP (2)
Analysing
srEP (3)
Summarising
Figure 6. Flow diagram of sIPD method with combined the collected IPD.
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Figure 6 shows a flow diagraln Of the SIPD metlЮd with co血bined the collected IPD.In
this chapter,each step in the SIPD lllletlЮd is d scribed in detail for two situations of meta―
anaけSiS data(continuous outcome and covari¨%and bin ry outcome and covariate)。
3.2.l  Continuous Outcome and covariate
Now,let
ymis_IPD={(物
,″ ,物):′=1,.・:,π`;|=1,…,Ⅳ},
yAD={協T,S::D ttT,SttDらc Lc,あS'tc):ら=1,…,Ⅳ}
whereンЪiss_IPD iS the uncollectld IPD for trialsづ=1,….,Ⅳ and yAD iS the AD sum―
Ⅲ iSed from them.Suppose that yAD Can be written by a functionん(1色iss_IPD);i・6.
yAb〒ん(ymぉ,IPD)。Now,the functionんtransforms the patient―speci■c observations into the
sample mean and the sample variance fOr each grOup in each trial.Then,we again consider
the IPD meta―analysis model(3.1)to ymiss_IPD,and assume that the covarittes of patientS
for each group in theづth trial follow the IЮrmal distribution(3.2)。If we again assutte that
z″and c″ are independent of eaCh Other,we have the conditional distribution of ν″given
物 aS(3.4).Here,parameters in the cOvariate distributions call le eStimtted as.(3.3),and
now let
ξ={いzЪ場1,金蒻c,場cl:に1,.::;Ⅳ}. (3.10)
And also. let
η=01,…"φN,θ,μ,笹,御,弓)
be parameter lo be eStillllated.  ヽ
(3.11)
Combining IPD and AD For the case that some trials provide IPD and the others
provide only AD trials, let
Yrpo : {(au, ni.j, zij) : j : L,.. ., n;i i, : N * 1, . . ., lf'}
be the collected IPD for trials a : .AI * 1, . . . ,.0/'. As in the case that all trials provide only
AD, we consider the IPD meta-analysis model (3.g) to YmissJpD and Y1pp, and assume that
the covariates of patients for each group in the ath trial follow the normal distribution (8.2).
Here, pa,rameters in the covariate distributions can be estimated as (3.8), and let
ξ={(九″`
T,∂
銑T,あzづc,∂夕c):づ二1,…。,Ⅳ
`)。
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(3.12)
And also, let
η〒0ぃっφⅣ,θ,μ篠,割:弓) 0。10
be parameter to be estimated. For both cases, each step in the SIPD method is now described
from frequentist and Bayesian perspectives.
SIPD method via'frequentist.procedure
Step (1): Generating SIPD
Let /(Ymbs-rpD;€,4) be a density function of the missing IPD with parameter 4 in (3.11),
which is equivalent to product of bivariate normal densities from
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′∈T
.   (3。
14)
プCC恥
(1期:1,|み懺1),
fOr l〒1,…・,Ⅳ andブ=1,…。,πづ。Here,ηυをT,σLT,mνをc and弓づc are giVen as(3.6)and
(3。7)。Then,We draw the SIPD(say ttsttIPD)士°m the cOndi ional distributbn of ymiss_IPD
giVen yAD and a known parallneter 01ue脅;i・e
ン宝iss_IPD～∫(】亀iss_IPDlyAD;ξ,ク) (3.15)
where f is computed by maximising the following likelihood under an assumption known as
CAR (Coarsdning at R^andom) by Heitjan and Rubin (1991);
^fL1p(ril: 
"f 
(Yao; 
€,q) : I t (YmissrpDif, ?)dYmiss-tpo. (3.16)JY4p-lr1Y-tuu-r"o1
This means that
rl- arg max ,Lap(4).
tl
Once obtaining the parameter estimate, fi, we can get -R sets of SIPD by repeated drawing
of (3.15); say
4s‐静D={(場],″り,場]):ブ豊1,:・,a;`=1,.:。Ⅳ} (3.17)
for r=1,.:.,R.To use(3.15)for genertting the SIPD,it is necessary to calculaje(3.16)
in an explicit form and then draw from∫lymiss_IPЬlyAD;ξ,う)。 Below,we describe how to
cabultte LAD(η)and draw ttom∫(ymisttPDlyAD;ξ,巧)。
Calculating LAD(η): The cabulation of the hkelihooo(3.16)requlres the integration
with respect toン鶴 よIPD OVer the region that satisiesンЪぉ針IPづ=ん(yAD)・In particular,by
the derivation in Appenditt A,this is given by
五
¨ =″×ニ レ リ
¬ηザ%η
{二靴 、
あT二鶴タリ
2+sLJ}
<毛∂切ぽeマ{_轟〔働C―πra2+sれゎ‖ こわ
離lmiw磁種Ⅲw賎3V蛇岬満hmご°いCm面斡a
Drawing from∫(ン缶ss_●DlyAD;ξ,う): We can easily derive∫(ンЪぉs_lPD;ξ,う)士Om(3.14)
wth the known pttameter脅,薔hb∫(ymiss_PDlyAD;ξ,わis ttmcμL tb dertt exactけbё‥
cause its sampb space is de■lled on the region that satisfles yAD=ん(4iss_IPD)・ThiS
IIneans that sample nlealls and sample variances of outcome and covariate for each group in
each triaL whiCh is computed by llsing indi宙d al outco血ё and covariate values drawn iom
∫(ymiss_PDlyAD;ξ,う),lllluSt be equivabtt to the correspondhg san■pb■leans and sall■pb
vaHances in yADo We here desc五be how to achわve t e drawhg i6平∫(塩ぉHPDlyAb;ど,0
by using a samoling technique proposed by Lindqvist and Taraldsen(2005).
Now,we represent the observation vectors ibr each group in theづth rial as follows:
yjT■{物:ブ∈T}, ZづT={物:JCT}, 洸c〒{物:ブ∈C}, Zづc={物:J∈C}.
Recall that ymiss=IPD dёl10tes the ullcollected IPD;ioe。(物,″″,物)fOrづ豊 1,….,Ⅳ and
ブ=1,.…,ηづ.BeCallse ofbetween・・trial and between…group independence,we have the density
functiolls of ymぉ_IPD given yAD andうaS f011ows:
∫(鴫sHPDlyAb;ξ,巧)=
Ⅳ
Π ノ麟 TlλЪ  S'じT;九z赤,磁1)∫け 州 レ Ъ sLDZ州;0
づ=1
×∫(Zづclれc,S'づc;命z`c,∂多,c)ノ(yづcl働c,S:ac,ZづC;う)。 (3.lo
The五,the rth set ofSIPD forthe ttitFial(say y脚,7界,y andz髪)are gellerated as random
samples drawn■om the corresponding conditional dist■bution n(3.19), hat indicates the
following sequential sampung procedllre:
z界 ～∫しぼlλT,SZが為zぼ,場T),
y鼎lz鼎 ～ ∫(yづTI働T,S3赤,Z界;巧)
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and
z肥 ～ ∫(zづclac,s,`c;仇zづc,∂,づc),
.    ｀      y肥lz肥 ～ ∫(ytcl働c,Sれc,Z肥:り。
Thおmeans that Wettst draw ztt attdthenytt byllsing Z‖,whic  tte applid br drawing
z肥攣dy肥。
Hera z‖repre“飢s sallapbs ttOm the cOndtbnal mrmtt dおtributbn given sampb mem
乃T■ndきample variance sZをT.A resuh by LindqviSt and Taraldsen(2005)described in
Append破B allows 9hO tO achieve this drawing as follows:         _
Z界={乙T tt γ″~υづszづT:′∈T} (3.20)
where{υ″:ブ∈T}denOtes ηづT random samples from the standard normal distribution,
こぅand sιづare a santpb mean and a sttaple variance sulnmarbed iom them respective撃
hthermor%letthg μ and tt be the 9oHeSponding con■ponёttS in脅,we Can 4raW y‖五
similar way t6(3.20)as f0110W∬
H: {gu, + Gt,+ td@*l - Znr) * 6';(u;i - a) 'r e T} o.21)
where {rti , j € T} denot es n1a random samples fro- lhe standard normal distribution, o6
and βればe a sal■■ple mean and a sampb variance summarised.■o五them respect v v And
also          i
& =
S蒻ザ=&T-lΣしあ
]―乙→0″TQ)
ForブcC,(3:20)and(3.21)can be used in a similar manner,except that(ル+～w) n(3.21)
is replaced byル.
Combining IPD and AD For the case that some trials provide IPD and the others provide
only AD, the collected IPD are essentially utilised for supplementing to the computation of
f. Because all trials are independent of each other, we compute fi by maximising product of
the likelihood for the IPD trials and that for the AD trials; i.e.
fi: arg max Zlpp(d x Leo(q)
n
―(μ+争″)Szを,υづ十
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(3.22)
Where LAD(η)iS already given by｀(3.18),and ttIPD(η)iS giVen by
五IPD(η)=∫(yIPD;ξ,η)=
′
K×
:虫1二券
exp{―ダ号
鱗 ―|―
ら
'″
Tμ
ttT筆″弯れ―御 ″″物 ―プ }02鋤
where F is a constant term unrelated to η.Once obtainingぅ士om(3.22),we can get R sets
of SIPD in the same way as(3.20)and(3.21).
The fact that we can usёthe IPD froln a part oftrials ofFers a■Other s01ution to compute
う。The IPD triab partけprOvide inbrmation ofらcT物 a d Σ′cc物,indiCating that
EM(Expectation Maxmis,tiOn)algOrithm、by Dempster,Lard and Rubin(19771 can be
applied for the computation ofぅ.
EM algorithm: Because of between-trial and between-group independency, we have
the density function of Ydss-1pp and Yrpo as fodo*st
ノCК
=ぉ
針IPD,MPD;ξ,η)皇Π ∫幌 T,Zば,洸C,%C;九zぼ,場Ъ 仇 ぁc,場c,η)。
こ=1
The EM algorithm repeats two steps of calculatiOn referred to as E¨step and M―step.In
3step,given(yAD,yIP5)and a Current parameter ttlue巧同,we Calculate the following con…
ditional expectation:
+Σ  bg∫(洸Ъ Z犯,丸c,zκ;金zぼ,磁D九″c,場c,づ
 ｀           づ=Ⅳ+1
where the secOnd term can be derived as the bivariate normal denStties ttom(3.14).In the
flrst ternl,we need to calculate the conditional expectations ibr the sufncient statistics of
Σ物,Σ4,Σ場,Σる,Σ物為,
Σ物,Σ場,Σ場,Σ場,Σ物物
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for j=1,...,N.Among theIIl,we have                              ｀
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allld the same calculatiollls are applied to those for J c C.For the COnditiona1 0xpectations of
乃 ∈iν″物 and Σ′cc物,We here use Monte Carb approximation.An algortthm in which
the integratiOn cJculatiOn in E¨step iS replaced by Mo“e Carlo approximation is known as
Monte Carlo EM(MCEM)algOrithm by Wei and Tanner(1990)。The MCEM algorithm■st
draws 3 sets of ymisttPD(S赤理 も.PDおrb二1,…,3)士Om the dondtbnal distrわ麒 iol s
∫(塩iss_IPDlyAD;ξ,うM),where the samphng′teёhnique by Lindqvist型I Tarddsen(2005)can
be used in the same way as(3.20)and(3.21).Then,平haVe
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η
¶hese iterative of E―step and M―step are repeatedly implemented until a convergence condト
tion holds,and the flnal parameter valte is regarded asぅ。              `
Step (2): Fitting IPD meta-analysis model
Step (1) produces.R sets of SIPD for trials i: L,.:.,ly'i i.e. Y$l.r-r"o for r 
- 
1,...,R in
(3.17). We can now fit the IPD meta-analysis model (2.L) to each of SIPD (or each of SIPD
combined with the collected IPD). This produces .R sets of MLEs for parameters of interest
and their variance estimates; for instance. the within-trial treatment-covariate interaction
efiect, ti#, rrti{il)) for r : 1,...,ft.
Slep (3) : Summari,sing esti,mate.s
In Step (3), resulting estimates for each set of SIPD are suitably summarised. For example,
suppose that there is an interest in the posterior distribution of Tw; say zr(TyylYap), which
is written by
f
" 
(fw 
I 
Yeo ) : J " 6* lY*is,-rpo ) "f (Ymiss-rpo I Yao ) df*r.ot"o. (3.24)
We here consider an approximation known as Poor Man's Data Augmentation (PMDA) 2 by
Wei and Tan“I(1990.GiКュ竹 ,(棚,7(州))and颯,IPDおrr=1,…"R,thQ PMDA
2 approximates the posterior distribution of ?W as follows:
7「(7、vlyAD)π (3.25)
where
-'"$lr*1,-,"o)w,:v(i{il 1/2-.\ ry--
" tT(id r*1,-,"o) (3.26)
The weights tr.r, for r : !r...rR are importance sampling weights designed to correct for
the fact that one is not sampling from /(Y^1ss-reolYap), and PMDA 2 provides an unbiased
estimate of the observed data posterior (Steele, Wang and Raftery, 2010). The derivations
of (3.25) and (3.26) are detailed in Wei and,Tanner (1990). To obtain point estimate (via
the median of the posterior density)'and g5 per cent confidence limit, one must obtain the
required percentiles of the mixture distribution of .(3.25). Obtaining the desired mixture
percentile values (say c) requires solving
n
|w,"("wvly"H,-,ro) : 
"r:L
宙th rspect to御6ted%Wang and Raftery 201oo lfCOndde五ng缶=Σた1棚/R as押
estimator of ?w, the variance estimate for fry can be derived exactly, under an unrealistic
assumption, by using an idea known as type B estimator by Wang and Robins (1998); this
is beyond the scope of this paper.
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Combining IPD and.AD For the case that some trials provide IPD and the others
provide only AD, the posterior distribution of "p,'; say zr("yrylYao, Yrpo) is written by
zr(fwlyao, Yrpo) : I n(Wllzmiss-IpDr ylpo)/(y"riss-IenlYap, YIpp)dY-irr-rpo. (3.27)J
In the similar way as (3.25), the PMDA 2 approximates the posterior distribution of 7\)l,' as
follows:
π(術lyAttyIPJ%塾
υrπ(柿昭 電JPD xPJ
Σたl υr
where
wr:v(i?)r/2π(棚14籠HPD'XP→
π(仙14s.PD'XPJ
SIPD method via Bayesian procedure
Step (1): Generati,ng SIPD
Let /(Y*lserpDl{,4) be a Bayesian density function of the missing IPD given pa,rameter 4,
which has the same form ffi 
.f (Y-iss-rpn;€, rl). Then, we draw the SIPD (say Yisr-r"o) from
the posterior predictive distribution of V*;sr-1pp given Yap; i.e.
Fks‐IPD～∫(ymis,IPDlyAD,ξ)
where
∫(端轟.PPlyADiO=/∫(ymiまIPDlyAD,ξ,づ∫側 yALO“   ●・2の
and∫(塩siPDlyAD,ξ,η)is the density of γhsdPD given yAD and η,√171yAD,O iS the
posterior distribution ofη given yADo BeCause ofthe integration in(3.29),∫(ymiζIPblyAD,ξ)
can■Ot be expressed in a closed form. 」And al o,it is difllcult to draw sal■ples±olllll this
distribution directly;l however once obtaining samples ofthe parameter",We can achieサe the
drawing(3.28)app10Ximatett lf R Sets ofthe pttallneter values(say ηtt br l=1,….,R)are
drawn from the posterior distribution∫(ηlyAD,ξ),then the posterior predictive distribution
(3.29)can be approximated as bllow馴
∫lymttPblyAD,0ん島 元 ∫(ymi∬IPDlyAD,ξ,η哨r=1
(3.30)
This indicates that one random sampb ttom∫(ListtIPDlyAD,ξ,η回)correSpOnds to one ran―
do血sample hm∫(ymiss PDlyAD,ξ),and the r6petitbn Of thおdrawing yねlds R sets of
(3.28)
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SIPD(say司鳳鮮IPD f°rr=1,…。,R).The SIPD collsiSt Of the patient―specinc observatiolls
given as(3.17)。The approximttbn(3.30)requhes onё to draw iOm∫(ηlyAD,ξ)and then
むaw hm∫(ymぉHPDlyAD,ξ,η日).The htte.can be impblnetted by the“me prOCedure
fOr∫(ンЪiss_I,DlyAD;ξ,う)。 We.。w describe how to draw iomノ(ηlyAD,ξ)。
Drawing fromノ(ηlyAD,ξ): Drawing samples of η■om∫(ηlyAD,ξ)iS Straightforward
tO attieve by MaF卜9V Chain Monte cttlo(MCMC)methOd;in particular"use MetrOpOIS―
Hastings algorith. The p6sterior distribution of η can be written as
∫171yAD,ξ)∝∫(yADば,η)∫(η)
Whereノ(η)iS the density function for a prior distribution ofηnd we use a vague prior for this;
ioe・∫(η)∝σ」ユ′TheLノ(yADば,η)has the dameおrm器∫(yAD;ξ,η)in(3.16)。Theieおr●
br the purpose ofdrawing η国±o興∫(引yA5,ξ),the Metropols―Hおtings dgorithm takes the
お1lowing procedllres(Gelman cサal,1995):
1. Set a starting value η101,and iterate Step 2-4 for r=1,.1.,R.
2.Draw a sample ηl from a prOposal distributiOtt With density function ρ(ηlηレ
~1);i.e.
η*んρ(ηlηレ
~11).                    ・
We here assllme ρ(ηlη町~」)is a nOrmal density centered at ηレー可.
3.Comptte
α=mln{1ノ(η*lyAD,ξ)∫(η*)
'∫
(ηレ~lllyAD,ξ)∫(ηレll)∫・
4. Set nl') :4* with probability o, otherwise set 4hJ : rlb-rl.
For rapid convergence, we integrate out the parameter of trial-specific effects (6t,...,6x)
frgm f(r7lY6p,f), and then consider to draw (0,F,.yg,7ry) from their marginal posterior
distribution. This is because we need only the values of parameter associated with the
within-trial relationships (p and fW) to generate the SIPD.
Combining IPD and AD For the case that some trials provide IPD and the others
provide only AD, we draw the SIPD (say Yfr,rr-r"p) from the posterior predictive distribution
of Ylnisg-1pp given Yap and Ylpp; i.e.
礁 iss_IPD～∫(ン缶 ζ:_IPDlyAp,yIPD,ξ)
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wheた
(3.31)
and∫(ηlyAD,単Pp,ξ)おthe pOSterbr distribⅢlon 6f η given yAD・By the same reason de―
scribed above,■iS n cessary to■rst sample the parameter oヽs of η frOm∫(ηlyAD,yIPD,ξ),
and then draw ymぉ針IPD ttOm∫(y is,IPDlyAD,ξ,η‖).IR setS Ofthe paialneter vaⅢs(η回
for r=1,…。,R)are drawn from the pOstγiOr distribution∫(ηlyAD,yIID,ξ),the pOSterior
predictive distribution(3.31)can be approximated as fonow∬   ,
島 ■Jn.ttN島言飾 赫Jn∴η崎 (3.32)
This indicates that one random sampb iom∫(ン缶iss I「DlyAD,ξ,"回)correSpOnds to olle ran―
dom sampb iom∫(ymiss_IPDlyAD,yIPD,ξ),and the repet比10n Ofthis drawing yields R sets of
SIPD(γ胤鮮I二もおrr=1,…・lR).The approximttion(3.32)requhes one to draw缶o■
∫(ηlyAD,XPD,ξ)and th“draw iOm∫(ymぉ・ IPDlyAD,ξ,η
回
)。 The latter can be imple―
mented by the same procedllre for∫(ymぉ鮮IPDlyAD;ξ,脅)。 We now describe how to draw
iOm∫(ηlyAD,yIPD,ξ)。
Drawing fro]m∫(ηlyAD,yIPD,ξ): Asin drawing iom∫(ηlyAb,ξ),drawing samples Ofη
■Om∫(ηlyAD,yIP5,ξ)iS StraightゎIWard to achieve by MCMC method(MetЮp01iS―Hastings
algorithm)。The posterior distribution of η can be written as
∫171yAD,Mお,ξ)∝∫(yAD,XPDば,η)∫o)    ‐
where∫(η)iS the vague prior of∫(η)∝qFl・Because of between―trial independence,we have
∫(yAD,MPDば,あ)=∫(yADlξ,づ∫(4,Dば,η)・      1
where∫(yADで,η)has the sanleおIm as∫(yAD;ξ,η)h(3。16),and∫(MPDlξ,η)おderi“d by
the same form asノ(yIPD;ξ,η)●(3.2,).■om these resu■S,for the purpose of dravringあH
■9m∫(ηlyAD,yIID,ξ),the MetropouttHastings algorithm takes the following pЮcedllre年
1. Set a starting value η101,and iterate Step 2-4 1br r=1,.¨,」R.
.2.Draw a sample 
η*from a proposal distribution with density function ρ(ηlηレ
~J);ie.
η*～ρ(ηlηレ=11)。
We here assume ρ(ηlηレT」)iS a nOrmal density centered tt ηレ
~」。
∫(ymぉ鮮IPDlyA3,I15,0=/∫(ymぉ」PplyAD,ご,")√171■D,XPD,ξ)蒟
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3. Compute
. t. f,t*lY,-,rrpo,€)/(r.) Ia:min{l. '.'='= }.
t 
-' /(ro-tl lroo, rrpo, €) f Qtt"-tl) J
4. Set nl'l :4* withprobability a, otherwise set 4['l :ql'-r].
For the same reason described above, we integrate out the parameter of trial-specific effects
(h,...,dN,) from /(alY-6n,Yrpo,{), and then consider to draw (0,F,.yA,yry) from their
marginal posterior distribution.
As is the case for the frequentist procedure, the fact that we can use the IPD from a
part of trials offers another solution to draw from /(Y-iss-rpnlY4p,yrpo,€), which is known
as data augmentation by Tanner and Wong (1987).
Data augmentation The data augmentation is implemented by the following iterative
steps in terms of r :1, . . . ,8.
L. Choose a moderate positive integer B, and create draws as follows:
η甲 ～ ル 側
yAD,XPD90,端
塑.PD～∫(niss_IPDlyAD,ξ,ηレ'う。 (3.33)
for b=1,….,3.Her%九(ηlyAD,yIPD,ξ)den6tes an apprOximate posterior distribution
of η at iteration r,which is c6mputed at iteration r―-1.
2. Update the approxilnate posterior distribution Of η as follows:
3
れ 191yAあふ 助0■:日 型 雌 P静
助 。・
The pequence Of draws for ymiss_IPD and η缶om this iterat市e p ocedllre is known to coIIlverge
to a drtt frOmノ(]輛s.IPD,ηlyAD,MPD,0(Lttth and RuЫ乳 200幼.ThおiS motivated by the
fact that the approximate posterior distribition of η in(3.33),ル(ηlyAD,yIPD,ξ),iS easier
10d・甲 鮨Om than∫(ηlyAD,yIPD,ξ)。 hdeed,eatt ebment composingル171yAD,yIPD,ξ);ioe.
∫(ηl凛IIPD'yIPD,ξ)fOr b二1,…,3,can be derived exactly(Gelman θ
`α
l 1995).
More specincaltt We rewiito the IPD meta―analysis model(3.9)by uSing a matr破foim
Of
y=XηO+c,
c～N(0,弓I)。
Letting n : D{-tna be the total number of patients, y is an rz-dimensional vecto r of y6i for
i: L,,...,N'and j 
- 
1,.. .,tui,rX is an n x (lI'*4) design matrix, 0 is an n-dimensional
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zero vector,I is an π × η denttty matr破and ηO=(φl,…。,φN′,θ,μ,γA,7V｀)・If We again
お SllIIle the tue priOr Of∫(ηO,弓)∝け ヽ then we have the posterior distributb1 9f 170,弓)
gi“n ymぉ直PD and MPD,∫00,σ:lymお鮮IPD,MPD,0,aSおllow馴
ηol弓,ymiss_IPD,yIPD～N(oO,イ),
弓 1塩お直PD,XPD～IIllv―χ
2(π_Ⅳ′-4,s句
where lllv‐χ2(η_Ⅳ′-4,s2)denOtes a ran4om Variable■Om a scaled inverse ch卜squar
distributibn with scale parameter s2 and degrees of freedom π―ハ「′-4,and ach param ter
is given by           l
わ=(XTX)~lXTy o。34)
and
s2 :;+t 
_ 4(v - xrro)r(v - x4o). (3.3り
In the actual iterative procedures, the current value of Ymiss-rpD is substituted into (y, X) in
(3.34) and (3.35).
Step (2): Fitti,ng IPD meta-analysis mod,el
Step (1) producesRsetsof SIPDfortrials'i:1,...,N; i.e. Y$l""-rro forr- 1,...'Rin
(3.17). We can now fit the IPD meta-analysis model (2.1) to each of SIPD (or each of SIPD
combined with the collected IPD). This produces R sets of MLEs for parameters of interest
and their variance estimates; for instance, the within-trial treatment-covariate interaction
efFect,(棚,7(棚D brr=1,…R.
駒η6の1助mmarrisづηg estづπαιes
As is the case for the frequentist procedllre,we here consider the posterior distributiOn of
つヽV Wri“ёn by(&24)。■om tB¨ayeSial perspective,the posterior distribution ofっ、v can
be siIIlulttedけ■ISt drawi明琳 塩.PD iOm∫(路ぉJPDlyAJ,and tlei drawhg割士om
π(制1颯:.PD);le.
輛降鉾豊垂7rlulⅢP」
We apply a Rubin's (1937) combining rule in order to obtain a posterior mean and variance
for ?W, which is often used in multiple imputation. The rule approximates them as follows
o.3o
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豊』岬十害却輛
estimator of ?w, the variance estimate for ]yy can be derived exactly by using an idea known
as type A estimator by Wang and Robins (1998).
Combining IPD and AD For the case that some trials provide IPD and the others provide
only AD, the posterior distribution of ?w is written by (3.27) and can be approximated by
.R
zr(?wlYan, Yrpo) 
= 
"t 
f 
"(r*lv,l11,-pp, Yreo). (8.89)
Then, as in (3.37) and (3.38), the Rubin'rlrrrn rule approximates a posterior mean and
variance for .64r as follows:
E(7、、ァlyAD,yIPD)E IE(■、
～
rlymぉ,IPD,yIPD)lyAD,yIPD]
(Little and Rubin,2002)'
E(っ、vlyAD)???
?
?
?
???
?〓．
?
?
Ep(御lymiss_PD)lyAJ
l庄棚 (3.37)
and
Var(御lyAD) E IVar(′ンヽハ′llЪiss_IPD)lyAD]十VarIE(1内ぃ√lymis,lPD)lyAD]
(3.3鋤
where iw is given by (3.37). For frequentist inferences, we use (3.37) as an overall estimate
??
?
?
]1,y, and (3.38) as its variance estimate y(.i,w). If considering ?w : DLr lHlR as an
o。40)
and
Var(7、vlyAD,yIPD)= E IVar(7、vlXnぉs_IPD,yIPD)|】亀 ,yIPD]
十Var[E(γwlxttss_IPD,yIPD)lyAD,yIPbl
～
士二K爛十1斉ゼ蔦l抑―湖 2 (3.41)
??
?
?
where ?w is given by (3.40). For frequentist inferences, we use (3.40) as an overall estimate
fry, and (3.41) as its rnriance estimate V(.yw).
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Table V. The grouped form of data from group k in the ath study.
y=O y=1
fflO;k fl1tk
rnUk nv.k
fl* 
- 
rrUh n;k
3.2.2 Binary outcorne and covariate
We here consider the SIPD method only from the Bayesian perspective, for the case that
some trials provide IPD and the others provide onti AD'
SIPD method for combining IPD and AD via Bayesian procedure
Step (1): Generating SIPD
Assume that each AD trial is completely balanced at the patient-Ievel cova,riate; so that the
proportion of patients witln Z : L for the treatrnent group is asstrmed to be equivalent to
that for the control group. Letting uitc : lnurZt +0.5] (tA] is the largest integer not greater
than A) andns,itr:TLtk-nyi,.be the number of patients respectively with Z: L and Z:O
for group k in the ?th AD trial (i 
- 
1, . . . ,N), then the AD given by (**,no*,ntrr) can be
written as'marginal toials of.a2x2 contingency table in Table lTI, where the internal cells
msirr and rmr,ik reptesenting the number of patients respectively with (Y : L, Z : 0) and
(Y:IrZ:L) are not available. Now, for all trials i:.I,...,N', we assume that rnurc and
rn1676 follow a pair of independent binomial distributions respectively with probabilities ioex:
Pr(Y 
- 
LIZ :0,i,k) and p11i1r: Pr(Y : llZ : L,'i,k); i.e. moik 
- 
Binominal(ns.it*ps,ih) and
ruik 
- 
Binominal(nu.x,pr*). Then, we draw the SIPD for group k in the zth AD trial; i.e.
ms,itc (and, trLrik: Tnik 
- 
mo*), from the following posterior predictive distribution:
Pr(ms6plm6krno*rnr*)
f: I Pr(motnlmilr,n0iktnLiktPottc,,pun) f (PoiktPu*lmuc,ns,ih'n61)dp0tikdpuk. (3.42)J
for i :1, . . . ,.lf and k e {T, C}. Here, f (po*,punlrrli,k,'Itoit*n1i1r) is the density function for
the posterior distribution of (po*,pun) given m6, and is written as follows:
∫⑫oづん:plりたlπじた,ηoれ,,1づん)∝Pr(m`λlηoをた,ηlづた,pOづた,plをた)∫oOぅた,plをλ) (3.43)
prlorwhere f (ps;p',p16il is a distribution of (po*,pu*). Pt(m61xlns;k,nMk,poih,p1ap) is the
probability of a marginal total rmik : ntouc * m161, in Table V with unknown internal cells,
which can be derived as convolution of the binomial distributions for ms;re and, mutr:
P r (m 61xlnsik, n u,n, p o*, p uk)????? (脇)pg:1ド
ん
`1-pOり
た)れ0`ん~π°'ん
×仁づた世づ焼iλ)p職―πけに'ら1紛税うんTηん+m∝. o。っ
where
Itt : max(O rrrtritc 
- 
nux), ult : min(no*rrn*) (3.45)
represent the range of admissible values of msi.t so that rr4k : rmouc * rnyls and. T,,ip 
- 
mi4, :
noik-rns;p*n1ik-mt*are satisfied. And also, Pr(rns *lm;u,noiktnrihtpoikrprik) in (3.42) is
the probability of an internal cell given all the marginal totals in Table V. If the single internal
cellms1tc are drawn, the other internal cells can be identified uniquely as rmtik: rmik 
-,trloiikt
no* 
- 
rns6k and Uik 
- 
m161r. Letting
}or& : po*l(L 
- 
po*), \u,n = pu,x/(L - pun) (3.46)
be odds of po* and py;v respectivelg Pr(mo.i*lmehtTroiktnLikrpoih)p1i1r) can be derived as the
probability mass function of Fisher's non-central hypergeometric distribution (or extended
hypergeometricdistribution)withparameterofoddsratio\ak:\gil,f\1,'t,:
Pr(msiklmhh rloik t nuk, \*) : 惚)(二λTLiDλ》ん o.4つ
where l6p and uik are defined as (3.45).
Because of the integration in (3.42), the posterior predictive distribution of ms1t cannot be
expressed in a closed form. Also, it is difficult to draw samples from this distribution directly;
however once obtaining samples of pa.rameter (pg6tcrplet)r we can draw moik approximately
from (3.42). If .R sets of parameter values ("uv @[]u,p!1r01 r", r:t,...,R) are drawnfrom
the posterior distribution (3.43), then the posterior predictive distribution (3.42) can be
approximated as
二ぇ僻)(%∫螺?)λ雅0
■姉われは島喜Щ鶴れ脚¨ 嚇昴
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(3.48)
where the rth component in summation is the conditional probability of ms6k given m;k
and a known parameter of @tlu,e}lo). This indicates that a single ranilom sample from
Pr(msaTlm,iktTloiktnt*,,p\ln,p$lo; .ottu.ponds to a single random sample from the posterior
predictive distribution (3.42), and the repetition of this drawing yields R sets of SIPD (say
@tlo,*l[1 n, r : 1,. . . , ft). Therefore, we generate the simulated IPD for the AD trials
by using the approximation (3.48), that requires us to draw from f (pot*,py,tlmi1r,nsi,tcrn1.ita)
and then draw from Pr(msir,lmiktTloiktny,n,p{}n,P$Ll. * now describe how to draw from
these distributions in more detail.
Drawing fr on f (potn,,Putclmilr,nott",nu,t)
Now. Iet
yAD ={(πづん,・oづた,ηlをλ):づ=1,…。,Ⅳ,たc{T,C}},
yIPD ={(mO,た,πlを1,電0`λ,πlづλ):`=Ⅳ+1,‥。,Ⅳ′,た∈{T,C}}
Where yAD iS the AD summarised from the llncollected IPD for trials t=1,…`,Ⅳ,and yIPD
is the conected IPD for trialsづ=ハ「+1,。,。,r√′・HerO,we assllme the following model for the
logits of pOじλ and Plをた;i・eo the logarithm of(3.46):
log,\sa6 : ao6r
log )1ag : dlct (3.49)
log )oet : aot * 02,i,
log,\i;a : a:: *gZt
We now consider to draw parameters in model (3.49), and then produce thc values of pou"
and. p161, by using model (3.49). Letting
n : (aOC, otIct o;1T t on, 0)
be a parameter vector to be drawn, wb have
∫(ηlyAD,yIPD)∝ ∫(η)∫(yADlη)∫(yIPDlη)
N
=√(→Π Π Pr(mづλレ∝た,ηl焼,づ
づ=1たc{T,C}           .
N′
×Π Π Prい∝た,mLルcた,πlた,η)
を=N+1たc(T,C}
47
where /(r?) is the density function for a prior distribution of 4 and we use a vague prior for
this; i.e. /(q) x 1,. Pr(milrlnsi.htflti.kt4) is given as (3.44), andPr(msilr,mttlno*,n161r,11) can
be derived by using probability mass functions of Binomial distribution for ms;tc and, m161r;
i.e.
' 
Pr(moih, rnLikln12b nt* t rl)
l-^., \ /-.., \: l#) l;;r)tr*;r (1 - Po';'k)no;*-*oihptrnLik (L - pun)'ik-mtib (3'50)
where the corresponding'components in 4 are suitably substituted into p6.irr, p1i13, ),s;tr and.
)o*.
Drawing from f (qlYao,Yrpo) is straightforward to achieve by MCMC method; in par-
ticular Metropolis-Hastings algorithm. By using (3.44) and (3.50), the Metropolis-Hastings
algorithm allows one to draw .R sets of.4 from /(alYao, Yrpo); i.e. 4['J for r - 1, . . . ,R, which
takes the the similar implementing procedure described above. The rth set of pa,rameter
value, ,hl, is transformed into f*1, r[Ll and then fot]u,olLl uniquely.
Drawing frorn Pr(ms6rclm6ktrloiht"rnu,,p{}u,pf}*)t This drawing is equivalent to the
drawing from the Fisher's non-central hypergeometric distribution with a known paxame-
ter (7t[]u,p{}u). Wu can draw R sets of SIPD from this conditional distribution directly. Fog
(2008) supposed a fast algorithm to draw from Fisher's non-central hypergeometric distribu-
tion. we get.R sets of SIPD (say (*I[]*,*l]*1 r, r:1,...,R),which are transformed to
the binary data forrn of SIPD (Ati,*ti,4\ n j:L,...tTti and r 
- 
1,.. .,n.
ftep (2): Fitti;:ng IPD meta-analysis moilel
step(1)producesEsetsof sIPDforADtrials; i.t.(au,rui,r*\ fori:1,..., N, j:L,...,r;i,
and r 
- 
L, . . . 
, -R. We can now fit the IPD meta-analysis model (2.6) to each of SIPD with
the collected IPD. This produces 
-B sets of MLEs for parameters of interest and their variance
estimates; for instance, the within-trial treatment-covariate interaction efiect, ti{ill,yti{illll
for r=1,…。,R.
島η
`〃
′珈mmorおづηクcstづπαιcs
When there is an intcest in the posterbr distribution of御,we can use t“Rub ゴs(1987)
rule as described aboveo The rule approxinlates a poste五or mean and variance fOrっ、v as
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follows:
長ッ餞L玲→γ島二Ⅲ   い⇒
and
Va<γwlyAЬ,XPJγttΣly岬)+≒Iゼ≒IΣ]酬
二竹ア・  05鋤
r=
where iw is given by (3.51). For frequentist inferences, we use (3.51) as an o-verall estimate
]y,,, and (3.52) as its variance estimate y(Tw).
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4 Application and simulation studies
4.L Introduction
In this chapter, it is shown that the proposed methods described in Chapter 3 (method with
marginalising the missing IPD, and method based on simulated IPD) has many benefits for
inference of the treatment-covariate interaction. Especially for the within-trial relationships
between individual observations, the proposed methods work substantially better than the
existing approaches described in Chapter 2. Moreover, it is suggested that the proposed
methods could have a huge possibility to produce novel findings- We now outline objectives
and.regutts of each experiment
Simulation 1 In Chapter 4.2, weverify the performance of the proposed method with
marginalising the missing IPD in the case for only AD. We suppose the case where all trials
provide only AD, and compare estimates of the across-trial and the within-trial interaction
from the proposed method with those from a futl IPD analysis using the original IPD from all
trials. When variation in within-trial covariate distributions is small, the proposed method
provides accurate within-trial interaction effect estimates. This indicates that the proposed
method has a potential advantage to inference of the within-trial interaction, that is never
achieved by the existing approach.
Simulation 2 In Chapter 4.3, we verify the performance of the proposed method with
marginalising the missing IPD in the case for mixture of IPD and AD. We suppose the case
where some trials provide IPD and the others provide only AD, and compare estimates of
the across-trial and the within-trial interaction from the proposed method (and model (2.5))
with those from a full IPD analysis using the original IPD from all trials. When the number
of trials providing IPD is small (e.g. 1 or 2 of 20 trials), the proposed method provides more
acclrate within-trial interaction effect estimates than model (2.5). If meta-analysts consider
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how many IPD trials should be collected to preserve a desired level of statistical power, the
proposed method requires them to collect smaller number of IPD trials than the existing
model (2.5).
Application to hypertension data In Chapter 4.4, we illustrate the SIPD method via
Bayesian procedure through an application to the hypertension data. We are again interested
in how age modifies the treatment effect on change in SBP (follow-up mimrs baseline), and
demonstrate how the SIPD method produces the across-trial and the within-trial interaction
efiect estimates in the case for mixture of IPD and AD. The main gain from the SIPD method
is to improve the standard error of the within-trial interaction effect estimate in compa,rison
with the existing model (2.5), especially when the number of trials providing IPD is small. A
potential benefit of using SIPD is also discussed in the context of a subgroup meta-analysis
which is never conducted by using model (2.5).
Simulation 3 and Simulation 4 In Chapter 4.5 and Chapter 4.6, we verify the ob-
served performance of the SIPD method via Bayesian procedure in two situations: one is the
situation where a single continuous outcome and covariate are observed from each patient
(Simulation 3), and the other is the situation where a single binary outcome and covariate are
observed from each patient (Simulation 4). In particula,r, it is ensured that the SIPD method
provides more accurate within-trial interaction effect estimates than the emisting model (2.5)
or model (2.9).
4.2 Simulation 1-: Performance of the proposed method with
marginalising the missing IPD in the case for only AD
We here supposed that all trials provide only AD, and focused on the treatment'covariate
interaction estimated by fitting the MR model (2.2) and,the method with marginalising the
missing IPD described i'' Chapter 3.1. The MR model (2.2) canbe used only for the inference
of the across-trial interaction (B); whereas the proposed method allows one to estimate both
the across-trial and the within-trial interaction (7a and 7y,'). Some practical differences
between 7A and Tw are as illustrated in Chapter 2, lhat highlighting the pitfall of using
?e to make inference about iyy. In particular, we were interested in how the log-likelihood
(3.8) computed by using only the AD available recovered the information on the within-trial
relationships.
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4.2.I Design of Simulation 1
We considered that the true models for generating individual outcome and covariate values
from patients in each trial were written as follows:
″了{
鶴zぅ ～N
物1鶴zづ～N(πzづ,ιZ),
物 lα″,物,あ～N(20+5″″+0.05物+0.05″″乙+0。1″″(物―易),弓),
J=1,…。,800,づ=1,….,10
?
?
?
?
J∈C
プCT
(30,1の,
(4。1)
where the numbeis of patients for the treatment group in each trial were assumed to be
equivalent to those for the control group;ioe.ηづT=η`
C=400 forづ
=1,。.。,10.In the IPD
meta―nalysis model(2.1),inferellce of the within―trial interaction is mainly arected by:the
varittce parameter in within―rial covar ate distributblls,σ
',and,the variance pallameterin cond“bnal diStributiollls of tt given物,弓.The stan ard errors of the wi hi■tlial
i武eractbn efFect estimttes tte expected to becoIIle smaller郎鵬increases and tt decreas,s
(SimmOllS and Higgins,2007)。We here controlbd these parameters by the following sce■ario殷
σZ∈{20,40,80)and b:∈{10,20,40}.
The il■opblnenting pЮcedure was as bllows.Firsttt We set pttameters of tt and弓
among 9 scenariOs,and then according to the true model(4。1)With p talllle ers set in the
previOus step,we generated 10,000 sets of meta‐analysis data.vOr  speciflcaltt We generated
mean covaritte for the dth trial,mzじ,■om N(30,10)and cOvariatO values for patients in the tth
trial iom N←ηzり,σ
')giVen mzを
and σZ,and thett outcome values for patients given c6variate
valueso SeCOndtt We sumttarised'the IPD from争■10 triab to the AD repFesented as sample
■eans and sample variances of ind市idua1 0bServations in each group and trial.Fina転we
lllletttmalysed the ADけ:(i)ittillg the MR五odel(2.2),and(li)applying the proposed
IIlethod.In each analysis,we computed estimates of β and their root mean square ёrrors
(RMSEs)缶om the MR model(2.2),and thOSe of7w an4 γA from the proposed method.The
RMSE for β waS C6ntputed by using γA=0・05 as Ls true value.These results were compared
with the resuLs from the fun IPD analysis.
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4.2.2 Results of Silnulation l
Table Ⅵ shows RMSEs and mean biases for the acr6ss¨trial interaction in each scenttiO.
Fitting the MR面od l(2.2)to the AD ioh all trials natllra■y provided estimateS O五ly of
the across―trial interaction,β,whOSe RMSEs ttd mean biases were equivalent to those for
仏 ■Om the fun IPD analysis.However,as mentioned abovei the estimates of the acFOSS―trial
interaёtion must be interpreted difFer9ntly■om those of the wtthin_trial interaction.For
&ampb,in a scenario 9f弓=40 and σ
'=20,Figure 7 shws scatler pbtS of Z―
,lues for β
■Om the MR model(2.2)aga nst z,values for仏(pall 1 0n th  lei side)and ttv(pane1 0n
the right side)frOm the fun IPD analysis.The vertical and hori2ontal lillles represent Z_values
of l.69(ioe.the d市ision between statistical,ignincance and llon―s tt 6f a Oneside
hypothesis test at 5 per cent level for HO:β=0 0r HO:っ、v=0)・ObViOllsly ttom Figllre 7,
estimates of β and theL standard errors■om th  MR model(2.2)were equlvabnt to those
Of γA frOm the full IPD analysis.For 10,000 Sets of meta―analysis data,99.7 per cent ofthe
fun IPD analyses provided signincant results for ttv,While only 26.3 per cent Of analyses by
t“MR modёl(2・2)were Signincant for β.And also,for 73.4 per cent of ttalyses,缶'S■・Om
the full IPD analysis were signicant and β'SfrOm the MR model(2.2)were nOn_signfcant,
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、?
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?
?
??
?
?
?
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?
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?
?
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?
?
?
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?
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Z‐valuesofβ Oomth9MRmodel o.幼
‐2024
Z‐values of β
“
m the MR mode1 2o
写igure 7.Scatter plots of Z―口 ueS Ofβ rom the MR model(2.2)agaiIISt Z―values of仏
(pane1 0n the lett side)andれv(pane1 0n the right side)■om meta_analyses ofIPD ttom all
'         10 trials.  ,
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Table M. Root rnean square errors and mean biases for estimator of across-trial
treatment-covariate interaction effect.
Root IIIlean squaale error of
β Or ttA
Mean bias of
β Or ttA
σ:σ子 MR Proposed (Full-IPD). MR Proposed (Full‐IPD)■
20
40  40
80
20
20  40
80
20
10  40
80
(0.053)
(0.054)
(0.054)
(0.038)
(0.038)
(0.038)
(0.000)
(0・000)
(0・000
(0・000)
(0・000)
(0・000)
(0・000)
(0・000)
(0000)
0,054    0.054
0.054    0.054
0.054    0.054
0.038    0.038
0,038    0.039
0.038    0.038
0.001    0.0 1
0.000    0.0 1
0.000    0.0 0
0.000    0.0
0.001    0.0
0.000    0.0
0.000    0.0
0.000    0.0
0.000    0.0
?
?
?
?
?
?
?
?
?
?
?
?
?
?
?
?
?
?
?
?
?
?
?
?
?
?
?
?
?
?
?
?
?
?
?
0.028
0.027
0.027
MR: Fit the MR model (2.2)to the AD from all 10 trials.
Proposed: Apply the proposed method to the AD from all 10 trials.
rResults by fitting model (2.1) to the'full IPD from all 10 trials.
o!: Yafiance parameter in within-trial corrariate distributions.
oj: Variance para,rneter in conditional distributions of outcodes.
Table VII. Root mean square eriors and mean biases for estimator of within-trial
treatment-covaxiate interaction effect.
Root mean square error of
tw
Mean bias of
"fw
σ;  σ: Proposed (Ful卜IPD)中 Proposed (Fbll-IPD)-
20
40  40
80
20
20  40
80
20
10   40
80
0.220
0.206
0.202
0.201
0.197
0.116
0.195
0.171
0.061
(0.032)
(0.023)
(0.016)
(0.023)
(0.016)
(0・011)
(0.016)
(0・011)
(0.008)
-0:091
-0.083
-0.082
-0.090
-0.081
-0.017
-01090
-0.068
0.005
(0・000)
(0・000)
(0・000)
(0.000)
(0.000)
(0・000)
(10")
(0・000)
(0・00p)
PToposёd:Apply the proposed lrlethod to the AD■oIIrl a11 10 trials.
すResults by ntting model(2:1)to the full IPD from a11 10 trials.
σ::Variance parametりin宙thill―trial covariate distributions.
σ::Variance paFamet∝in conditional astributions of outconles.
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indictting thtt meta―analysёs llsing the MR model(2.2)welle prone to fail in detecting the
treat甲Ⅲ―coVariate intettctiOtt in cOmpariSon with meta―allalyses 9f e original IPD from
a11 10 trials.
In principle,the proposed method can be llsed for estimⅢing nOt Only th  acЮss―trial
interaction efbct but also the within―trialinteraction efFecto The R〕√SEs and the lnean biases
fOrね士Om the proposed method were equivabnt to those iom the MR model(2.2)血d the
■■IPD ttmlysis(Tabb Ⅵ),indicating the bttlikelihood(&8)preserved information on the
across―trialinteraction prёisett Table ⅥI shows RMSEs and mean biases for the within―trial
interactionっ、v ln each scenario.Note that,ln the full IPD analysis,we used the IPD from
an lo triab,while in the proposed method,we used only the AD■om an lo trial  When弓
was large(eog.弓=40)and σ
'Was smal(e・
go α=2o,柿■om the propbsed method had
a large RMSE with a negative bias.On the other hand,astt b6caIIle sm争Ⅱёr and t b9c lne
lttger,the RMSEs and the lnenn biases iom the proposed method decreased imllllediⅢe撃
Especia町おr the scenarios of弓=10 and σ,=80,the proposed hethod ofered the smallest
RMSコforれv with approxihately zero bias.T“se reSuLs suggested that the proposed
methOd required a relatively_large variallce in within―trial covariate distribut onもto estimate
the within―r al interaction precisett and in su9h situatiollls the use Qfthe log―likelihood(3.8)
could recover information on the within―trial relationships iom the AD trials.
4。3  Silnulation 2: Performance of the proposed llllethod with
marginalising the missing IPD in the case for mixture of
IPD and AD
We here supposed that some trials provide IPD and the others provide only AD, and focused
on the across-trial and the within-trial interaction effect estimated by fitting the existing
model (2.5) and the proposed rnethod described in Chapter 3.1. Some practical benefits
of combining IPD and AD are as illustrated in Chapter 2, highlighting that using only
the collected IPD or reducing available IPD to AD had some disadvantages due to loss
of information. We were now interested in how estimates of the within-trial interaction from
the proposed method became close.to those from the full IPD analysis according to the
proportion of trials providing IPD: The standard errors of iw from the proposed method are
expected to become smaller as the ploportion of trials providing IPD. We also assessed the
gains from the proposed method beyond the existing method by Riley et at. (2!008).
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4.3.L Design of Simulation 2
We considered that the true models for generating individual outcome and covariate values
from patients in each trial were written as follows:
?
?
?
?
?
?
．
?
?
．
?
?
?
?
?
?
?
―
?
〓??
π″JんN(30,10),
物lmzづ～N(れ方ぅ,σZ), (4。2)
協′|″り,Z″,乃～N(20+5″″+0.05z″+0.05″″乃+0・1"″(Z″―乃),40),
ブ=1,…。,400,t=1,…。,20
where the numbers of patients fol the treatment group in each trial were a,sumed tO be
equlvalent to those for the control grOup; i.e. ηづT=πOC=200 forづ==1,。, ,20。 We gave
the total number of trials by 20,and controlled the number of trials providing IPD by 5
scenarios of l,2,4,亀16 of 20 trials(corespOnding軌the numbers of trials providing AD
were givett by Ⅳ∈{19,18,lQ 12,4})。As br the variance paralllleter in within―trial covariate
distributiolls,We COnsidered σZ=80 foF the AD triab,and contr01bd that for the IPD triab
by?SCenarios of罐∈{40,80}.
‐
 The impleIIllenting procedllre was as follows.Firsttt We set the n―ber of IPD trlalS
and tt in the IPD trials aIIlong 10 scenarios,and then according to the true II10del(4。2)
with parameters set in the previous step,we generated 10,000 sets of meta―analysis data.
Secondtt acCOrding to t“scenari0 0f the number of IPD trials,鴫summarised the IPD
■om trialsづ=1,…。,Ⅳ to the AD.Finaltt We met″attalysed a m破tllre ofIPD and AD by:
(i)fltting model(2.1)or mOdel(2.4)to the COlbcted IPD ttom trials t=Ⅳ+1,…,20,(ii)
sllmmarising the collected IPD ttom trialsづ=FV+1,.…20 to he AD and then itting the
MR Illlodel(2.2)to the AD■om al1 20 triab,(iii)■tting model(2.5)to the mixtllre pf IPD
and AD,(iv)applying the propo6ed method to the mixture ofIPD and ADoln each analysis,
we comput,4 eStimates and their RMSEs for β frOm lnethod(ii),and those for 7w and γA
■om method(1),(lii)and(市):These r,SultS Were compared with those obtained by fltting
model(2.1)to the IPD■6m a11 20 trials(full IPD analysis).We also col■■puted sample mean
of absohte diferences between estimates of 7、v ttom model(2・5)or the proposed method and
thOSe iOm the full IPD arnalysis,which was i“e ded to evaluate hOW far the p9int edtim乱9
obtained by ntting model(2.5)ёr the SIPD method is apart iom that obtained ttom the full
IPD analysis on average.
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4.3.2 Results of Simulation 2
Table MII shows RNISEs and mean biases for the across-trial interaction in each scenario.
The MR model (2.2) again provided estimates only of the across-trial interaction, B, whose
RMSEs and mean biases were eqirivalent to those for fa from the.full IPD analysis. Fitting
model (2.1) or Q.a) honly the collected IPD had seriously large RMSEs for fa when the
proportion of trials providing IPD wd,s small (e.g. 2 IPD trials and 18 AD trials). This is
because the precision of the across-trial interaction efiect estimate depends. on the number
of trials involved and between-trial heterogeneity. Table D( shows RMSEs and mean biases
for the within-trial interaction in each scenario, The RMSEs and the mean biases for f1a,,
obtained by fitting model (2.1) or (2.4) to only the collected IPD got close to those from the
full IPD analysis as the proportion oJ trials providing IPD increased.
The strategy of combining IPD and AD by fitting.model (2.5) or the proposed method
yielded accurate results for the across-trial interaction, as well as estimates of the within-trial
interaction which got close to those from the full IPD analysis according to the proportion
of trials providing IPD. Including AD trials remarkably improved the RMSEs for ia in
compa.rison with analyses using only the collected IPD. Fitting model (2.5) and the proposed
method provided similar RMSEs and mean biases for la of each other, which were eqrrivalent
to those from the fuU IPD analysis. The results for the within-trial interaction from model
(2.5) were equivalent to those from analyses using only the collected IPD, indicating model
(2.5) correctly allowed only the IPD trials to estimate .y1a,,.
The main gain from the proposed method was to improve RMSEs for i1ar. In most
scena,rios, the proposed method provided muph smaller RMSEs than model (2.5),especially
when the proportion of trials providing IPD was small (e.g. 1 IPD trials and 19 AD trials, or
2 IPD trials'and 18 AD trials). The absolute differences also confirmed that |1ry's from the
proposed method were, on average, located closer to those from the full IPD analysis than
model (2.5).
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Table Mtr. Root mean square errors and mean biases for estimator of across-trial treatment-covariate interaction effect.
Root llllean square erro■of
β Or ttA
Mean bias of
P ot 'Y^
い0
Number of trials            Obs‐ Mode1                         0bs‐  Model
provlding IPD  σ
'    MR  IPD  (2.5) PropOSed (ndl―
IPD)*    MR   IPD   (2.5) PropOSed (Full―IPD)*
り" ‖ 器 Nl l椋朧 格囲 ・淵l N 滞滞 (淵)
″" 翻 :脚lI:W躙 81瑠 棚1瑞淵1淵1(酬l
″η 』躙 }場肥 :器 8剛 :胤滞 胤 :胤 ‖爛3
8/20       ::     :::1:  :::::   :::::    ::::;      |::::]        三:|:::   ::::I   三 i ::  三:i::|     |三:::::|
“″0 認 :耀艦 :耀 朧: 器旧 端1瑞端1端1(ⅧI)
MR:FL the MR model(2.2)to the AD from a11 20 trials.
ObsI¨PD:Ftt model(2.1)to the c。llec ed IPD.
Model(2.5):Ftt n2odel(2.5)to the mixture of IPD allld AD.
Proposed:Apply the proposed method to the ni就ure ofIPD and AD.
*R■ultS by ttting modd(2.1)to the full IPD■om a11 20 trials.
σ,:Varittce paranleter in within,trial covariate distributions for patients in the IPD trial.
NA:Not avallable.
Tbbtre DL Root mea.n square errors a,u,il mean bias€s f()r estima,tor of within-trial trestmeni-covaxibte iid€ractioD effect, a,nd sa.mple mears of
abcolute differences betwe€n estiEates froe nodel (2.5) or the propoeed method and thos€ ftom the firll lpD.ala,lysis.
Root mean squaxe error of
tw
Meall bias of
,W
Mean of
absolute
difrerence
Number of trialS
pro宙ding IPD  σ: Proposed (FulHPD)* Proposed (Fun‐IPD)中
NIodёl
(2.5)  PropOSed
???Model
(2.5)
Obs‐
IPD
Model
(2.5)
0
〇
1/20
2/20
4/20
8/20
16/20
0.082
0.057
0.059
0.044
0.045
0.033
0.034
0.024
0.025
0_018
(0.01o)
(0.016)
(0.016)
(0.016)
(0.016)
(0.016)
(0.018)
(0.016)
(0.020)
(0.016)
0.002
0.002
0.001
0.000
0.002
0.000
0.001
0.000
0.000
0.000
(0.000)
(0・000)
(0・000)
(0.000)
(0.000)
(0.000)
(0.000)
(0・000)
(0・000)
(0・000)
0.011
0.006
0.011
0.006
??
??
?。
??
??
??
??
??
??
?。
0.101   o.lol
O.069   0.069
0.072   0.o72
0.050   0.050
0.050   0.o50
0.035   0.035
0.036   0.036
0.025   0.025
0.025   0.025
0.018   0.018
0.001    0.Ool
O.000    o.ooo
-0.002  - 2
-0.001  -o.o01
0.001    0.0 1
0.000   -0 ool
O.000    o.ooo
O.000    0.0
0.000    o.ooo
O.000    0.ooo
0.079     0.060
0.054     o.o44
0.056     0.044
0.038     0.032
0.038     0.033
0.025     0.023
0.025     0.023
0.016     0.015
Obs―IPD:Fit model(2.1)tO the c。1lec ed IPD.
Model(2.5):Ftt model(2.5)to the mixture ofIPD and Ap,Proposed:Apply the propOsed method to the mixture ofIPD and AD。
中Resulte by ntting model(2.1)tO the full IPD缶o五au 20 trials.
σ::Varianct paranleter in wthiitrial cO―iate distribut olls for patients in the IPD trial.
4.4 Application to hypertension data: Illustration of the pro-
posed method based on simulated IPD
Consider the hypertension data, and we illustrate the SIPD method via Bayesian procedure
described in Chapter 3.2. To imitate situations involving IPD for some trials and only AD
for others, we considered scenarios as in Chapter 2.1; where only a tidited number of trials
(from L ta 4of the 5 trials) provided IPD and the other trials just provided AD. In each
scenario, we carried out analyses by: (i) fitting the MR model (2.2) to AD from all 5 trials,
{ii) fitting model (2.5) to the mixture of IPD and AD, and (iii) applying the SIPD method
to the mixture of IPD and AD. In both parts (ii) and (iii), the analyses were run for each
possible combination of IPD and AD trials. In each scenario, we cou.pared the results with
those from a meta-analysis of IPD from all 5 trials (full IPD analysis).
In the SIPD method, for the iterative process of the Metropolis-Hastings algorithm to
draw I : 500 values of parameter, we discarded the first 5,000 samples in order to prevent
dependence on the starting values. Moreover, we took a sample at only every 1,000th iteration
in order to avoid autocorrelation between the samples taken. The sdme iterative process wiII
be taken in Simulation 3 and Simulation 4.
The gains from the SIPD method
The results of estimates and their standard errors for the across-trial and the within-trial
interaction, averaged across all possible combinations of IPD and AD trials in each scenario
are shown in Table X. As for the across-trial interaction, the SIPD method produced estimates
closer to the full IPD analysis compa,red to model (2.5) regardless of the number of IPD trials.
The estimates of 74 from model (2.5) were also close to those from the MR model (2.2). For
each scenario in Table X, we also found an important difference between results for the
within-trial'interaction effect from model (2.5) and the SIPD method. When compa.ring
fy,,'s from model (2.5) with those from the full IPD analysis, model (2.5) provided point
estimates located in a positive direction on average, with large standard errors. This is
because model (2.5) allorws only the IPD trials to estimate the within-triil interaction, and
thus the estimates and their standard.error for tw by fitting model (2.5) got close to those
from the full IPD analysis as the available number of IPD trials increases. The SIPD method
improved both the estimates of Tw and their standard errors to be 'closer to the correct (full
IPD) estimates, especially when the number of IPD trials was small. The most benefit came
?
?
Table X. Average of estimates and their standard errors for treatment-covariate interaction
effect when analysing change in SBP (follow-up minus baseline) from hypertension data,
where estimates are averaged across all combinations of IPD trials.
Average of
estimate
Average of
standard error
Number of trials  Model
providing IPD‡ (2.5)
Model
(2.5)  SIPD
Across-trial
interaction
effect 7a
5/5・
4/5
3/5
2/5
1/5
0/5+
-0.662     ‐
-0:766 -0.662
-0,766 -0.663
-0,768  -0.665
-0.781  -0.667
_01766     -
0.464     ‐
0.468    0.464
0.463    0.464
0.464    0.464
0.464    0.463
0.466      -
Within-trial
interaction
effect ?w
5/5*
4/5
3/5
2/5
1/5
0.087
0.091
0.117
0.166
0.244
0.090
0.096
0.103
0.105
0.055      -
0.063    0.063
0.084    0.076
0.130    0.097
0.258    0.131
Model(2●):F■model(2.5)to the mixture ofIPD and AD.
SIPD:Apply the SIPD metlЮd to the mixture ofIPD and AD.
*Results by ttting model(2.1)to the full IPD iom al1 5 trials.
十Results by ntting the MR model(2.2)to the AD■om』1 5 trids,
lThe numbers of combinatiolls of trials proⅥding IPD are 5,10,10 and 5
in the scenarios of l,2,3 and 4 1PD trials,respectively.
in the scenario of I IPD trial, in which estimates of Tw were iqr :0.244 (s.e. - 0.258) from
model (2.5) and iw : 0.105 (s.e. : 0.131) from the SIPD method; the latter is much closer to
the full IPD analysis result of iw :0.087 (s.e. - 0.055). This shows that the SIPD method
allows both using the AD trials and IPD trials to estimate the within-trial interaction, and
- this adjustment based on the AD trials is usefuI especially when the number of IPD trials is
small.
Table X also shows that the difference between the estimates of nar (and its standard
errors) from model (2.5) and those from the SIPD method became smaller when increasing
the number of IPD trials. The results in the scenario of 3 IPD trials and 2 AD trials were
similar to those using the full IPD, and the.results in the scenario of 4 IPD trials and L
AD trial were alrnost equivalent to those using the full IPD. These results suggested that
model (2.5) could provide s,rfficiently accurate estimates of the within-trial interaction if a
high proportion of IPD trials are available.
For each scenario, Figure 8 shows estimates of ?w and their standard errors obtained by
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(a) For the scenario that I hial provides IPD and 4 trials provide AD
(b) Forthe scenario that2 trialsprovide
Figure 8. Estimates and their standard errors for within-trial treatment-covariate
interaction effect when analysing change in SBP (follow-up minus baseline) from
hypertension data in the scenarios that: (a) 1 trial provides IPD and 4 trials provide AD,
(b) 2 trials provide IPD and 3 trials provide AD, (c) 3 trials provide IPD and 2 trials
provide AD, (d) 4 trials provide iPO and 1 trial provides AD.
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(c) For the scenario that 3 trials provide IPD and 2 hials provide AD
(d) For the scenario that 4 trials provide IPD and I trial provides AD (*The name ofAD hials)
Figure 8 (continued)..
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fitting model (2.5) and the SIPD method for each combination, where the horizontal axis
represents the name of each IPD trial with sample size in parentheses. For example, in the
scenarios of 2 IPD trials and 3 AD trials, names of 2 IPD trials and sum of sample sizes from
2 IPD trials are shown, and also in the scenarios of 4 IPD trials and L AD trial, names of L
AD trial and sum of sample sizes from 4IPD trials are shown. The heavy'solid line represents
the results from the full IPD analysis, and thus the closer results to this line are regarded as
superior ones in the sense of matching the full IPD analysis. For almost all combinations of 1
IPD trial, the SIPD method provided estimates of ?w and their standard errors which were
located closer to those from the full IPD analysis than model (2.5). These were particularly
considerable when the number of patients included in the IPD trial was small (e.g. HEP,
EWPHE and MRC-2). Similar findiilgs were seen for the scenario of 2 IPD trials, although
the results by the 2 methods were closer, and almost equivalent in the scenario of 4 IPD trials
and 1 AD trial.
The difference between the results from modet (2.5) and the SIPD method is clearly
dependent on the proportion of available IPD in all patients, not just the number of IPD
trials, because the difference between methods decreased in the case of large sample size of
IPD trials in Figure 8 (".S. SHEP and Sy-Eur). For this viewpoint, we computed the number
of patients involved in the IPD trials for all the 30 combinations from Table X. Figure 9 shows
一 Full‐IPDo Modclo.5)
+ SIPD
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Figure 9. Estimates and their standard errors for within-trial treatment-covariate
interaction effect sorted by the proportion of available IPD in all patients when analysing
change in SBP (follow-up rhinus baseline) from hypertension data.
65
estimates of ?w and their standard errors from model (2.5) and the SIPD method for all the
scena,rios, which includes 30 results sorted by the proportion of patients involved in the IPD
trials. As before, the difference between the results from model (2.5) and the SIPD method
became larger when the proportion of patients involved in the IPD trials became smallerl in
addition, the differences rapidly diminished when IPD for over 40 per cent of patients was
available. Thus, the StrPD method had most notable benefits when the proportion of patients
involved in the IPD trials was low.
The SIPD method could bring meta-analysts some other potential advantages, rather
than just provides fry and its standard errors which are closer to those from the full IPD
analysis in comparison with model (2.5). Once obtaining the SIPD, one can apply any IPD
meta.analysis approaches to each set of SIPD combined with the collected IPD. We here
Name of IPD Trial Patient
(Sample Size) Subgroup (Age) Mean Difference [ 95 per cent CI ]
Full IPD analvsis
>70
← 70 -
-
‐10.78 [-11.86, -9.69]
‐10.78 […11.77, ‐9,78]
??
EWPHE
(172)
MRC‐2
2651)
SHEP
“
736)
Sy‐Eur
(4695)
>70
← 70
メ70
← 70
>70
← 70
>70
← 70
>70
<=70
-
-
-
-
‐10.25 [‐11.91, ‐8.58]
‐11.40 [‐13.35, -9.44]
‐9。95[‐H.64,‐826]
‐11.77 [113.75, 9¨.76]
‐10.47[‐12.04, ‐8.91]
‐11.11 [‐12.89, -9.33]
‐10,70 [‐11.82, ‐9.59]
‐10.85 [-12.01, ‐9.70]
‐10.78 [‐11.86, ‐9.69]
‐10.78卜H.77,‐9.78]
:
‐14 ‐12       ‐10
Mcan DifFerence
Figure 10. Pooled estimates of mean difierence on change in SBP (follow-up minus baseline)
between groups and their 95 per cent confidence intervals for 2 patient subgroups of age.
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considered a situation of exploring beneficial efiects in specific patient subgroups, and meta-
analysed these subgroups within each trial in hypertension, which were identified by age of
patients. Obviously, model (2.5) for combining IPD and AD cannot provide any findings for
this. We allocated each patient in the IPD trials and each simulated patient in the AD trials
to 2 or 3 subgroups according to the following scenarios: (i) whether age of the patient is
more than 70, or not, (ii) whether age of the patient is more than 73, 67 or more to 73 less,
or not. Using covariate values generated for patients in the AD trials enables one to estimate
pooled treatment effects for each patient subgroup. We here considered onlf a situation
where 1- trial provides IPD and the other 4 trials provide AD. Figure L0 shows the pooled
Natllle ofIPD Trial      Paticnt
(Sample size)    SibgrOup tAge) Mean Difference [ 95 per cent CI ]
Full IPD analysis
>73
く=73,>67
く■67 --
-
=9.78 [‐11.03, …8.52]
‐11.57 [‐12.60, ‐10.54]
‐10.78 [‐11.69, ‐.87]
?? >73く=73,>67
<■67
>73
く=73,>67
く■67
>73
く=73,>67
← 67
>73
く=73,>67
← 67
>73
く=73,>67
← 67
‐10.03 [‐12.42, 7¨.65]
‐10.76 [‐12.03, ‐9.48]
,1lt76 [‐14.47, ‐9 06]
-9.48 [‐11.96, ‐7:01]
‐10.92 [‐12.19, ‐ .66]
‐12.18 [‐14.96, ‐9.40]
‐10.02 [‐12.24, =7.79]
‐11.08 [‐12.33, ‐9.83]
…11.25 [‐13.64, -8.86]
‐10.47 [-11.98, ‐8. 6]
‐11.00 [‐12.18, ‐9.81]
-10.82 [‐12.31, -9.32]
‐10.43 [-11.97, ‐8.89]
‐11,11[-12.25, ‐9 98]
‐10.79 [‐12.02, .9.56]
EWPIIE
(172)
NIRC‐2
σ651)
SIIEP
“
73o
Sy‐Eur
“
695)
-
-
-
-
-
:
…14
:
‐12 ‐10
?
?
?
?
Mean Difference
Figure 11. Pooled estimates of mean difference on change in SBP (follow-up minus baseline)
between groups and their 95 per cent confidence intervals for 3 patient subgroups of age.
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treatment effect estimates and their g5 per cent confidence intervals for the scenario (i) of 2
patient subgrgup. The uppermost block represents results from the full IPD analysis. The
names of 1 IPD trial are depicted in the left hand side, squares and horizontal lines around
them denote the pooled treatment efiect estimates and their 95 per cent confidence intervals
respectively.' When the 1 IPD trial had large sample size (e.g. SHEP and Sy-Eur), results
for each patient subgroup from the SIPD method were similar to those from the full IPD
analysis. Figure l,L also shows the pooled treatment efiect estimates and their 95 per cent
confidence intervals for the scenario (ii) of 3 patient subgroup, and the same findings were
seen for the IPD trials with large sample size.
4,5 Simulation 3: Performance of the proposed method based
on simulated IPD in the situation of continuous outcome
and covariate'
Flom the results in the application to the hypertension data, it was shown that the SIPD
method via Bayesian procedure provided estimates of the within-trial interaction closer to
those from the full IPD analysis than model (2.5), when the number of IPD trials was small
and when the number of patients involved iU thc IPD trials was small. To check this finding,
we here focused on the within-trial interaction effect, and compared some statistical properties
of iw obtained by the SIPD method with those obtained by fitting model (2.5) under some
settings of controlled parameters and the number of patients involved in 1 IPD trial and g
AD trials.
4.5.1 Design of Simulation 3
We considered that the true models for generating individual outcome and covariate values
from patients in each trial were written as follows:
″」二
{|| :[:ヽ
,
πzを～N(九z,∂λ),
物lπ″`
～
Nいz`,σ:),
物レγ,物,場～Nψづ+θ″″+β物+仏″″屍+割″″場 ―乃),弓),
ブ=1,…。,ηづ;づ=1,…1,10
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(4。3)
血ere the true paramet∝s exceptおrw andtt weregivenas,stim¨es by fltting IIlodel(2,1)
to IPD ttom 10 trials origina■y repo ted in Wang cι al(2005),with Change in SBP as an
outcome;e.go θ墨-4.958,ル=-0・042 and ttA=~9・079,The total llumber of patients was
given by Σ泄1あり=6,000,and each group had the same sttpb size as η州〒ac=ηづ′2.ゅz
叩d tt are the mean covariat,value across all the 10 trids and its varianc%based on the fact
that the Wang's data gave ttz〒Σ胆1花/10=62.69押d∂乳 〒Σ胆1修一九z)2/(10_1)=
180.8:We supposed that only l trial provided IPD(the other 9 trialS provided AD),and
contro■ed the number of patients involved in the l IPD trial by s破scenarios of 60,300,600,
1,200, 2,400 and 4,800; so that the proportions of patients with available IPD were given
by l,5,.10,20,40 and 80 per centi reSpectively.The 9 AD trials involved almost the same
n―ber of patients for eaCh sCenario.
We here considered σ,=100 fOi the 9 AD′trials,and controlbd that for the l IPD trial
by 3 scenarios of σ,c(25,50,100}.TheSe scOnariOs of tt bad lls t9 a situttbn that.the l
IPD trial provides information on the within―trial interaction less than oi equal tO the other
AD trials,We also gale nへV==0・2 and弓=200 so that the power to detect the within―trial
interaction estimated iom the fullIPD analysis becomeぎhigh enough for each,cenario.
The in■plementing procedllre was as follows.FIsttt We set the llumber of patients in―
volved in the l IPD trial and σ,おr each of 18 scenarios,and then generated 5,000 sets of
雫ta―叫alysis data according to the true model(4.3)with parameters set in t“preViOlls step
for each scenarioo Second軌for each set in each scenariO,we summarised IPD for 9 ofthe 10
trials to AD.Fina■y9we a lysёd the m破ture ofIPD and AD by 2 methods:model(2.5)and
the SIPD method.In each attalysis,we computed mean‐square error(MSE),  bias and
menn standard error forれv.We alSO Col■■puted sample mёan 6f absolute difFerences between
estimntes of 7w obtained by fltting model(2.5)or the SIPD methOd att those obtained
iom the full IPD analysiso Morёover,we estiηated the type l dror rate and the statistical
power with one―sided hypothesis test at 5 per ce■leve1 0f Signincance for HO:鍋v=O and
Hl:?、
～「<0.     ・
4:5。2 Results of Silnulation 3
The results of 1/1SE, mean bias and mean standard error for each scenario are shown in
Table測.In each ScenariO,the SIPD method provided substantially smaller MSEs and mean
standard errors in comparison with m6del(2.5),espeCially when the proportion of patients
with available IPD was low(e.310r5per cent)and tt VraS Small(ag・罐 =25).The
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results of the absolute difFerences also show that the point estiinates 6f 7、v±oln the SIPD
method were,on averagё,10c t d closer to thosё
=om a full IPD analysis(of a11 10 trials)
than model(2.5).The difFerence between the results from model(2.5)and the sIPD method
WaS the largest for the scenario of l per cent ofpatients with available IPD andσZ=25, nd
becaIIlesmttbr as the proportionofpatients withavailabb IPD tts higherandσz illcreased.
These indicate that the SIPD method could attuSt the estilllllate of 7w and its standttd
error from the IPD―only analysis closer to those from the full IPD analysis using additional
information fr6m the AD trials,especially when the sample size of the IPD trial was small
and the variation in patients cOvariatё within the IPD trial was small. For example,in the
scenario of 5 per cent of patねnts in the IPD trid and罐=25,the MSE was reouced by 50
per cent using the SIPD Inethod(MSE豊o.o51)ra her thall model(2.5)(MSコ=0。111);
similttly the standard error was reduCed COnsiderably by using SIPD(mett S.e`=0.248)
ratr¨ than llllodel(2.5)(Inett Soe.=0。328)。
However,in the scenarios of sllllaller proportion of patients with available IPD,the esti―
mates of～、v from the SIPD method were more suttect tO a positive bias.For exanrlple,the
menm bias iom the SIPD method for the scenario of l per cent of pat“nts with availab e
IP⊇and∂
'=25 was O。
107,and thus ttw Was larger than the trlle value of御=-0.2 on
average.This i due to the infltellce of the information on the withill―trial relationsh ps ttom
the AE)trials. The SIPD method allows one to extraCt the information on the within―rial
relationships iom the AD trial by using(3。18),and thus we ain substantially smaller MSES
and mean standard errors for ttw in cOn■paFiSOn o model(2.5).On the other hand,this
information ttom the AD trials also pun the estillnates ofっ、v in a positive dhection when
the pr6portionヴpat e ts with available lpD is extremely bwI Therefore,in scenarios of
leSS 10 per cent of patients with available IPD,there is a trade―ot the large gain in MSE
nnd ptandard error cOmes at the 9xpenSe of a bias.The bias is negligible in all■letlЮds
for 10 per cent or over,and the SIPD method still has gain in MSE(up to abOut 40 pёr
Cent)ald standard error(up tO about 20 per cent)in Situations between 10 and 40 per cOnt
of patients with available IPD.Figure 12 also shows the estimates of 7、v for the scenario
Of罐〒100,which are aranged in asceiding order of estimates iom model(2.5)and then
Suit¨ly Sm。Othel by taking an avertte ofeach 100 estimates.■om Fttllre 12,the difFerence
between results obtdned■Om mOdel(2.5)ano the sIPD method were seen dynamicalしIn
partic■lar,fOr the l per cent of patients in l IPD trial in panel(a),it Was con■rmed that
the estimateS froi the SIPD method were much cbser to tbose iom the full IPD analysis in
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comparison with model (2.5), and sufiered from a positive bias.
Figure L3 shows the type I error rates and the power for fyy estimated by the 3 methods
for each scenario. In the scenarios of 1 and 5 per cent of patients with available IPD, the
type I error rates from the SIPD method were highly conservative. F\rrther, when the true
within-study interaction v/as zero, the SIPD method did not produce biased estimates of Tw
unlike when "yry was 
-0.2 (results not shown in Table )il). Therefore, the conservative type
I error rates for the SIPD method are likely due to overestimated standard errors of ?w,
even though the standard errors were smaller than those from model (2.5). In the scenarios
of over 10 per cent of available IPD, the SIPD method had better type I error rates close
to 5 per cent- The powers of model (2.5) and the SIPD method to detect the true negative
interaction were very similar. The SIPD method was marginally better when 10 to 40 per
cent of patients were in the IPD trial.
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Table測。Mean_squtte errors,Illleall biases and mean standard errors for ёstimttor of within―trial treatment―covariate lnteraction erect,and
san■ph means Of absolute diferellces between esti血at s hm model(2.|)or the sIPD method(for IPD ttom ollle trid and AD ttom nine
trial)and those hm the fullIPD analysis(br IPD iom al1 lo triab).
Mean-squa,re error of
tw
Mean bias of
')w
Mean standard error of
7W
Mean of
absolute
differencePer cent Of
total patients in
the IPD trial  σ多
Model
(2.5) SIP⊇(Full¨IPD)中
Model
(2.5) SIPD(Full-lPD)*
Model
(2.5) SIPD
Model
(2.5)  SIPD  (Full―IPD)*
N
た0
L per cent
5 per cent
10 per cent
20 per cent
40 per cent
80 per cent
0.612   0.098
0.303   0.088
0.147   0.067
0.111   0.051
0.054   0.035
0.026   0.020
0.055   0.033
0.027   0.020
0.013   0.011
0.027   0.021
0.014   0.012
0.007   0.Oo6
01013   0.011
0.007   0.006
0.003   0.003
(0・001)
(0.001)
(0・001)
(0.001)
(0.001)
(0・001)
(0・001)
(0・001)
(0.001)
(0.002)
(0・001)
(0.001)
(0.002)
(0.002)
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0.164   0.145
0.231   0.191
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0.058   0.057
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0.434   0.235
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0.002  0.050   (0.000)
_0.008 0.041  (o.o00)
-0.001 0.020  (0.000)
0.001  0.008   (0.000)
0.002  0.020   (0.o00)
-0.001 0.007  (0.001)
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0.002   0.011
0.000   0.003
-0.001  0.001
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(0・0 0)
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(0.037)
(o.o37)
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-0.001 0.000  (―o10 1)
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001  0.001   (o.ooO)
0 000  0.001   (o.ooO)
o.082 0.081 (0.058)
0.058 0.958 (0.047)
0.041 0.041 (0.037)
.046
.026
.014
0.045
0.026
0.014
Model(2.5):Fit model(2.5)to the mixture ofIPD ttld AD,SIPD:Apply the SIPD IIlethod to the m破ture ofIPD ald AD.
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4.6 Simulation 4: Performance of the proposed method based
on simulated IPD in the situation of binary outcome and
covariate
Through an application to the hypertension data and Simulation 3, in the situation of contin-
uous outcome and cova,riate, the SIPD method via Bayesian procedure improved the existing
method by Riley et al. (2008) in the sense of matching the full IPD analysis for inference of
the within-trial interaction. We here supposed a situation wheie a single binary outcome and
covariate are observed from each patient, and focused on the across-trial and the within-trial
interaqtion effect estimated by fitting the existing model (2.9) and the SIPD method via
Bayesian procedure described in Chapter 3.2. The methods were applied for the case that
some trials provide IPD and the others provide only AD. We were again interested in how
estimates of the within-trial interaction from the proposed method became close to those
from the full IPD analysis according to the proportion of trials providing IPD.
4.6.L Design of Simulation 4
We considered that the true models for generating individual-specific outcomes and covariates
from each study were written as follows:
[0, j€c.nij: \ )[ 1' 
'€T
zij 
- 
Bernoulli(m"i),
a4.lrii, zi.j, Zd - Bernoulli(q;7),
to| i9+ - -2 - 0.5rii * 0.5zii * 2r6iZi * nii(zii - 2t),t_gij
j : L,...,400,'i, : L,..., 10
where the numbers of patients for the treatment group in each trial were assumed to be
equivalent to those for the control group; i.e. n41 : nic : 200 fori, :1,..., L0. We gave
the total number of trials by L0, and conlrolled the number of trials providing IPD by 4
scenarios of L,2,4, 8 trials (the numbers of AD trials were givenby N e {9,8,6,2}). We
also controlled the true proportion of patients with Z: 1 in each trial, m"; fori : L,. . . , 10,
by 3 scenarios of low-, moderate- and high-heterogeneity across trials. The true proportions
of patients witin Z: L for all 10 trials were given by {0.40, 0.40, 0.45, 0.45, 0.50, 0.50, 0.55,
(4.4)
75
0.55, 0.60, 0.60), {0.30, 0.30, 0.40, 0.40, 0.50, 0.50, 0.60, 0.60, 0.70, 0.70} and {0.10, 0.10,
0.30, 0.30, 0.50, 0.50, 0.70, 0.70, 0.90, 0.90) respectivelyl one for each trial. The standard
errors of ?a are expected to become smaller in the scenario of high-hetelogeneity on the
mean cova,riate (Lamb efi et at., 2A02). Each patient in each trial was allocated to a patient
subgroup with Z 
- 
L or Z :0, using predefined proportions for the trial, which varied from
trial to trial.
The irnplementing procedure was as follows. Firstly we set the number of IPD trials and
m",; for'i,: L;...,10 among 12 scenarios, and then according to the true model (4.4), we
generated 5,000 sets of meta-analysis data. Secondly, for each scenario, we summarised the
IPDfromtrialsi-L,...,ny'totheAD.Finally,wemeta-analysedamixtureoflPDandAD
by: (i) fitting model (2.9) to the mixture of IPD and AD, (ii) applying the SIPD method via
Bayesian procedure to the mixture of IPD and AD. In each analysis, we computed RMSE,
mean bias and mean standard error for ia and iy,,, We also computed sample mean of
absolute difierences between estimates of 7a (and 1a,') obtained by fitting model (2.9) or the
SIPD method and those obtained from the full IPD analysis. Moreover, we estimated the
type I error rate and the statistical power for 171,, with two-sided hypothesis test at 5 per cent
level of significance for Hs : ?W : 0 and H1 : .yq,' I 0.
4.6.2 Results of Simulation 4
The results of MSE, mean bias and mean standard error for the across-trial interaction are
shown in Table XI. In each scenario, the SIPD method prolided similar results to the full
IPD analysis. By contrast, the estimates from model (2.9) had, a negative bias, especially
in the scenario of low-heterogeneity on the mean covariate. The results of MSE, mean bias
and mean standard error for the within trial interaction are shown in Table )Otr. In each
scenario, the SIPD method provided substantially smaller MSEs and mean standard errors
in comparison with model (2.9), especially when the number of trials providing IPD was small
(e.S. 1 or 2 IPD trials) and the heterogeneity on the mean covariate was high. The results
of the absoluie differences also show that the point estimates of ,yys from the SIPD method
were, on average, located closer to those from a full IPD analysis (of all 10 trials) than model
(2.9). The difference between the results from model (2.9) and the SIPD method was the
largest for the scenario of 1 IPD trial and high-heterogeneity on the mean covariate, and.
became smaller as the number of trials providing IPD was larger and heterogeneity on the
mean covariate was lower. Figure 14 also shows the estimates of the within-trial interaction
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for the scenario of high-heterogeneity on the mean covariate, which are arranged in ascending
order of estimates from model (2.9) and then suitably smoothed by taking an average of each
100 estimates. FYom Figure L4, the difierence between results obtained from model (2.9) and
the SIPD method were seen dynamically. In particular, for 1 IPD trial and g AD trials in
panel (a), it was confirmed that the estimates from the SIPD method were much closer to
those from the full IPD analysis in comparison with model (2.9). Figure 15 shows the type I
error rates and the power for |qr estimated by the 3 methods for each scenario. The powers
of the SIPD method to detect the true positive interaction were higher than those from model
(2.9), especially when the number of trials providing IPD was small (e.g: L or 2IPD trials)
and the heterogeneity on the mean covariate was high.
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Table畑。Mea正卜square errors,mean biases and meall sta五did errors for o imator of across‐trid treatment―covariate interactiOn efFect,attd
sample mealls Of abs01ute diferences b"ween estimates from llllodel(2.9)Or the sIPD methOd and those from the full IPD analysis(fOr IPD
士om a11 lo trials)。             ヽ
Mean-square error of
i*
L〔ean bias of
γA
Mean standa,rd error of
it
Mean of
absolute
difference
Number of trids Covariate
providing IPD heterogeneity
Model
(2.9) SIPD(■lHPD)* SIPD(Full―IP⊇)Ⅲ
Model
(2.9) SIPD(Full‐IPD)*
Model
(2.9) SIPD
Model
(2.9)
ヽ
∞
1/10
2/10
4/10
8/10
Low
Moderate
High
Low
Moderate
Hish
Low
Moderate
High
Low
Moderate
High
1.119
0.304
0.082
1.275
0.351
0.090
1.170
0.315
0.083
1.156
0.312
0.081
1.262
0.316
0.087
1.178
0.317
0.083
0.011
-0.004
0.012
-0.035
0.018
-0.003
0.019
0.003
0.019
0.020
0.019
0.006
1.088
0.561
0.288
1.081
0.559
0.288
1.085
0.560
0.288
1.085
0.560
0.288
1.123   1.243
0.299   0.331
0.079   0.086
1.226   1.310
0.308   0.331
0.085   0.089
1.177   1.200
0.316   0.322
0.083   0.084
-0.150  -0.002
-0.156  -0.018
-0.072   0.0 5
-0.182  -0.044
-0.118   0.010
-0.079  -0.0 9
-0.089   0.017
-0.096   0.0 2
-0.037   0.018
1.064   1.099
0.550   0.568
0.285   0.291
1.060   1.087
0.549   0.563
0.285   0.290
1.069   1.088
0.552   0.561
0.286   0.289
0.221   0.189
0.159   0.097
0.086   0.041
0.202   0.167
0。146   0.086
0.077   0.036
0.169   0.144
0。111   0.o73
0.058   0.029
-0.019
-0.015
-0.013
0.020
0.019
0.006
1.080
0.557
0.287
1.086
0.560
0.288
0.085
0.049
0.023
0.079
0.040
0.017
Model(2.9):Fit model(2.9)10 the mixture ofIPD and AD,SIPD:Apply the SIPD method to the m破ture ofIPD and AD.*Results by ttting mOdel(2.6)to the full IPD alDm all trials.
Tbble Xtr. Mean-square errore, meaa biasee and mea,n statrdrxd emols 6r estieator of within-tdsl treatment-coi,axiate inieractiotr efiect,
and 8ailple mea,ns of absolute difierencee between estimates ftom model (2.9) ot the SIPD method ard tho6e froa the full IPD ana[ysis (frr
IPD ftom all 10 trials).
Mean-square error of
iw
NIeallL biaS Of
■ヽV
Mean standa,rd error of
Tw
Mean of
absolute
difference
Number of trials Covariate
providing IPD heterogeneity
Model
(2.9) SIPD  (Full―IPD)*
Ⅳlodel
(2.9)  SIPD(■lHPD)*
Model
(2.9) SIPD(Full―IPD)中
Model
(2.9) SIPD
N0
1/10
2/10
4/1o
8/10
0.026
0.027
0.037
0.026
0.027
0.038
0.028
0.027
0.037
0.026
0.030
0.038
-0.003
0.008
0.006
0.010
0.006
-0.001
0.001
0.002
0.003
0.002
0.010
0.020
0.163
0.167
0.194
0.162
0.167
0.194
0.162
0.167
0.194
0.162
0.167
0.194
Low
Moderate
High
Low
Moderate
Hieh
Low
Moderate
High
Low
Moderate
High
0.259   0.254
0.281   0.208
0.827   0.231
0.128   0.130
0.132   0.115
0.192   0.115
0.065   0.065
0.073   0.067
0.092   0.066
0.032   0.032
0.036   0.036
0.049   0.045
0.023   0.030
0.022   0. 32
0.007   0. 40
0.015   0. 18
-0.001  0.007
-0.003  0. 06
0.001   0. 04
0.005   0. 09
0」001   0.009
0.004   0. 05
0.010   0. 11
0.021   0. 20
0.513   0.490
0.531   0.454
0.714   0.473
0.361   0.338
0.373   0.331
0.445   0:344
0.256   0.231
0.264   0.234
0.309   0.257
0.181   0.168
0.187   0.173
0.216   0.200
0.388   0.388
0.398   0.348
0.579   0.380
0.266   0.267
0.257   0.245
0.311   0.259
0.156   0.156
0.170   0.164
0.186   0.165
0.068   0.067
0.066   0.065
0.078   0.075
Model(2.9):Fit model(29)to the m破ture ofIPD and AD,SIPD:Apply the SIPD method to the mixture ofIPD a■ld AD.
中RestltS by ttting model(2.6)to the full IPD iom all trials.
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Figure 14. Estimates of within-trial treatment-covariate interaction effect for the scenario of
high-heterogeneity on mean covariate.
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Figure L5. Type I error rates (three panels on the left side) a^nd powers (three panels on the
right side) for within-trial treatment-covariate interaction effect.
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5 Discussion and further developrnents
Meta-analysis with marginalising the missing IPD
We proposed a new meta-analysis method for estimating the treatment-covariate interaction.
As pointed out by Riley et a/. (2008), separation of the treatment-covariate interaction into
the across-trial and the within-trial effect is a clinically meaningful operation because these
effects might be difierent of each other due to ecological bias and/or trial-level confounding.
Indeed, for the hypertension data, we cannot conclude a negative interaction between the
treatment effect on change in SBP and age, with the across-trial effect estimated by using
the mean age iri each trial. This is because the within-trial interaction, which was estimated
by using age ofindividual patients, acted in the opposite diiection ofthe across-trial interac-
tion. Similarly for the home safety education data, the across-trial interaction between the
intervention effect'on provision of the stair gate and the proportion of male participants was
very different from the within-trial interaction between the.treatment efiect and gender of
individual patients. We here advocate that the MR model (2.2) ot model (2.7) does not give
suficient evidence for the patient characteristics.
In the proposed method, we a,ssume the IPD meta-analysis model for the missing IPD and
then marginalise its density with respect to the missing IPD. These processes produce the
log-likelihood (3.8) for AD available, and the use of this log-likelihood is useful to estimate
the within-trial interaction even when all trials provide only AD. The simulation studies sug-
gested that the proposed method provided the within-trial interaction efiect estimates with
moderately small RMSEs, and worked better when the variance in within-trial covariate dis-
tribution was large. The proposed method assumes that all trials are similar (exchangeable)
to each other apart from having a separate baseline (intercept). This strong exchangeability
assumption means that, conditional on the AD available (means and standard deviations
of each group), the missing information (such as the within-trial interactiotr, ?w, and the
covariate effect, p) can be informed approxiinately by meta-analysing the AD.
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The proposed method is also simply extended to the case for mixture of IPD and AD.
IPD meta-analysis has been advocated by many researchers, while the methodological de-
velopment for combining IPD and AD becomes increasingly important because practitioners
cannot always collect the IPD for all trials involved (Riley, Simmonds and Look, 2007; Ahmed,
Sutton and Riley, 20L2). Reducing available IPD to AD and focusing on just the across-trial
relationship leads to a loss of information and potential bias, and it is important to focus on
the within-trial relationship as much as possible. Through simulation studies, the proposed
method provided smaller biases and smaller MSEs for estimator of the within-trial interac-
tion, fry, ill ssmFaxison with the existing method by Riley et at. (2008), especially when the
number of trials providing IPD was small. And also, simulation studies suggested how the
biases and the MSEs for fry from the proposed method changed according to the number of
trials providing IPD. These results could offer a useful guidance if one considers how many
IPD trials should be collected to preserve a desired level of statistical power.
However, we recognise that the proposed method makes strong exchangeability assump-
tions and, as it stands, is only applicable to a narrow range of situations. In particular it
assumes that the treatment efiect and within-trial interaction'are fixed across trials. It would
be useful to extend the method to rand.om effects models to-allow for heterogeneity if possible
(Higgins, ffoqmpson and Spiegelhalter, 2009), and also allow a trial-specific covariate effect
(p;) and a trial-specffic error variance (oln). Indeed, a meta-analysis of the full 10 trials in
the hypertension data originally reported by Wang et al. (2005) would potentially require
this kind of modelling (Riley et a1.,2008). Riley et al. (20L2) notes that when there is
baseline imbalance a meta-analysis of randomised trials with a continuous outcome should
use analysis of covariance, and. we welcome consideration to this situation. Moreover, in the
proposed method, we assume that the covariate is normally distributed.. It would be neces-
sary to discuss how sensible the results from the proposed method are with respect to this
assumption. Finally, we only consider models for estimating one interaction, but of course in
practice multiple interactions might be of interest. Nonetheless, where the assumed criteria
a,re considered plausible or worth consideration in a sensitivity analysis, the proposed method
is a promising method for meta-analysts faced with combining IPD and AD.
Meta-analysis based on simulated IPD
The SIPD method proposed ofiers a novel framework for meta-analysis, and is also flexible
enough to estimate the treatment-covariate interaction whilst sepa,rating across-trial and
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within-trial efiects because it involves the scheme of ma,rginalising the missing IPD. Through
the application to the hypertension data, we demonstrated that the SIPD method provided
fesults for the within-trial interaction closer to those from the full IPD analysis than the
existing method by Riley et al. (2008). The most beneficial results were given for the cases
when the number of trials providing IPD was small or the proportion of patients with available
IPD was low. In such situations, the collected IPD trials may offer very little information
on the within-trial relationships, calsing model (2.5) to yield estimates of the within-trial
interaction with large standard errors. By contrast, the SIPD method utilises additional
information from the AD trials and, in comparison to model (2.5), can provide estimates
and sta,ndard errors closer to those from a full IPD analysis. This is particularly true when
given over 10 per cent and under 40 per cent of patients in the IPD trials, as the adjusted
estimators from the SIPD method were unbiased and had smaller MSEs and standard errors
for these situations in our simulation.
However, the simulation study revealed some limitations of the SIPD method. In par-
ticular, the adjustment by using the AD trials gave a bias in estimator for the within-trial
interaction in the cases when the proportion of patients with available IPD was u.de1 1-0 per
cent. And also, in the same situations, the SIPD method suffered from the conservative type
I error rates ofthe within-trial interaction effect, because the standard. errors from the SIPD
method were overestimated. However, in situations with over L0 per cent of patients in the
IPD trials, the SIPD method performed well.
' Using the SIPD enables one to apply any IPD meta-analysis approaches, and could have
a huge possibility to produce novel findings which is never provided by the existing meta-
analysis methods. Through the application to the hypertension data, we used the SIPD
method to meta-analyse patient subgroups within each trial identified age of patients. The
estimates of the within-trial interaction and its standard errors for each patient subgroup
could be utilised for a flexible trial design. To seek and find the further potential benefits of
using the SIPD will be discussed as a future problem.
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Appendices
Appendix A
The difficulty of using (3.16) is to integrate the density over a restricted sample space. Tsiatis
(2006) gave a general calculation to solve such problems. We here brief the Tsiatis's (2006)
approach, and describe how to integrate the normal density over the sample space that a
sample mean and variance are fixed. This calculation follows a discussion by Pullin (1979)
which proposed a method for generating random samples from a normal distribution with
known sample mean and variance.
Let X: (Xr, ...,Xx) be I( random va,riables, and. assume there exists a dimensional-
reduction transformation h(X), that is a K'-dimensional variable (K' <,I(). Also, assume
there exists a (K 
-K')-dimensional variable 9(X) that
X <+ {h(X),g(X)}
is one-to-one for all h(x).Let /(x) and /(h(x),g(x)) be the density of X and (h(x),s(x))
respectively. Consider random samples of X, fr 
- 
(rb...,rK), and suppose that .K'-
dimensional summa,ry statistics, h(r), arc only available. Then, an integration of J(X) over
a sample space with fixed D(r) is equivalent to an integration of f (h(r),,g(X)) with respect
to s(X); i.e.
(A.1)
If we consider X as normal random variables, h(n) as a sample mean and variance of r, the
desired likelihood (3.16) can be derived by.usign the relationship (A.1).
Let n1r... tfrK be independent random samples from a normal distribution with mean p
and variance o2. The joint distribution of (r1, . . . ,rk) is given by
d,F(r,i' ..r *x) : #*"rl-#ior- r,'] d'rr, "',nK'
Ior,,r r"ro" 
: I y P14,sT))d's(x)'
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We flrst consider the ibllowing Helllnert's transformation:
鷹みき。た一Kふ
IT     を鶴「″+1-りηもι=ム…,κ、
The inverse of(A。2)is readily 9btained as
″1=芸レ勇二― 紗],
a=η_+ [κ+ →々%―
“
→ψ統」,i=二…,κ
Using (A.3), a known result is led as
dF(au...''--\- 1 |- r 1^ 5 \1,ax) : @Fn.p l-rp lr? * Dtrr)ldau...,dax (A.4)
and
d,: F+ +, ", : *irrr\/K F-
Then, Att. . ., 916 independently follow a normal distribution with mean zero and variance
o2. We now consider a transformation of yt,. . . ,AK which follow the normal distribution as
follows:
″し,…っ姦)∝
"り
に_ッ2■[~嘉左滅|のいっ続・
(A.2)
(A.3)
(A.5)
The solution requires slightly difierent treatment by whether .fi( is odd or even. Now let
rt:(K-L)/2+€
where {:0 if K is odd and { :Ll2 if .fif is even, and introduce the set of transformations
Azm: J9* cosurz (A.6)
Uzm+t : \/e* sin u*, rn : Lr. . . ,rl - 2€
where 0 1u* 12tr for all m.If 1( is od.d, we use (4'.6) directly. If not, we must add
yx : Lt/e^ (A.7)
to (4.6) with equal probability L/2 for the * and 
-. 
Substituting (4.6) and (A.7) into (A.5),
we have
f r n ln-zt
d,F(ey...,an,t/Lt:.. ru,t-2t)o( exn | 
-' 
S 
- 
| I d,etd,vtle;r/zd"r1zt (A.8)l, 
'"' 
#-* J ,'=,
βπ=Ksし続Π(1-物),m=1,…,η-1,
J=1
^E
: €q: Kso lle = 2il.
J=L 
.
where each of the zrn, rn : I,. .. ,rl 
- 
1-, is located in an interval (0,1). The Jacobian of this
transformation is given by
while the sample variance is given by
' s2= 1g'fr k"*
Finally, we introduce a transformation of e1,...,e, into (s2rztr...rzrt-t) a's
|  |=鴫憚Π。一わ"・′=1
(σ
2)K/2eXpl_J::{(・Tμ)2_+s2,1.
(A.9)
(A.10)
(A.11)
Substituting(A.10)and(A.11)intO(A.8)and(A.9),IVe have
dF(s2,zl,…・,物-1,νl,・…,%-2ξ)∝
ゆ F二
り
,Xp卜寡 ]“め Π  
αtt Π に一づ く
れ十η+⇒d物.に■幼
π =l   π=1                 .
Therefore,iom(A.4)and(A.12),the dellsity of(μ,σ2)is giVen as follows except for terms
ullrelated to(μ,σ
2):
(A`13)
By using (A.13) in the context of the continuous meta-analysis data, we obtain (3.16):
Appendix B
In Step (2) of the SlPD-method, the uncollected IPD must be drawn from the conditional dis-
tribution given available AD; however, the density of this conditional distribution is difficult
to be expressed exactly. 
. 
This is associated with some issues on the conditional distribu-
tion given the sufficient statistics, discussed by Cheng (1984), Engen and Lillegard (1997),
Lindqvist and Taraldsen (2005). They gave general formula to calculate the conditional ex-
pectation based on the conditional distribution given the sfficient statistics. Especially, an
issue of sampling from the conditional distributions were considered. We here brief this ap-
proach, proposed by Lindqvist and Taraldsen (2005), for a simple case of univariate normal
'
distribution.
89
No■,let X=(Xl,…・, κ)denOte randOm variables following a normal distribution wtth
IIlean μ and varianCe σ2.Here,T=(X,Sx)iS the suttcient statistics for θ=(μ,σ),Where
ヌ=η-lΣ鷹1及and錢=(K-1)~lΣ鷹1(為―X)2.Let y=lyl,…"妊)dellote
random variables following standard normal distribution,and two functions of χ and τ are
deined by
χ(磁9)
7(鴫θ)
(μ+σ碗 ,・ :・,μ tt σyKl,
い+σび,σSび),
(B・1)
(B。2)
(B。4)
where′and tt stand br the mean and the variallce similarけdeined toアnd銭.The乳
there exists unique χ and 7 SO that the joint distribution of(χ(耽θ),7(耽θ)) S equivabnt
to those of(X,T)under the parameter θ.This mealls that,for given t=(曇,S″)andび,
θ≡θ(仏t).in WhiCh τ(仏θ)iS held is uniquely determilled as follows.
Thus, the random variable following the conditional distribution of X given ? : f is provided
as follows.
α耽の〒o(らの,∝軌→)=(″―島Sc,島Sc)。
珈 曖動=←+7…う+7→・
鉤二←+望なテニSc・ 9岳+7→・
(B。3)
It is easily shown that the probability distribution of. Xl is actually equivalent to the con-
ditional distribution of X given T : t. Finally, sampling procedure from the conditional
distribution give the mean and the variance is as follows: (i) generate random numbers
u: (ut,.. . ,uK) of t/, (ii) substituting u and t to equation (A.3), we get
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